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Etude de l’impact de l’administration de cisapride ou d’un placebo 
sur la vidange gastrique et la nutrition entérale précoce chez des 
patients de soins intensifs sous ventilation mécanique 
 
 
 
 
INTRODUCTION 
 
Ce travail de thèse reprend la physiologie et la patho-physiologie gastro-intestinale 
avant de se pencher sur le support nutritionnel nécessaire aux patients hospitalisés en 
milieu de soins intensifs. Dans la deuxième partie, une étude visant à améliorer l’état 
nutritionnel est détaillée et analysée. 
 
Les patients séjournant en milieu de soins intensifs présentent fréquemment de 
nombreuses co-morbidités (altérations de l’état nutritionnel et immun préexistant, 
maladies cardio-vasculaires, respiratoires et métaboliques ainsi que leurs 
répercussions) en sus de la ou des pathologies motivant leur hospitalisation. Une 
admission en milieu de soins intensifs implique un traitement agressif nécessitant des 
accès vasculaires, un tube endo-trachéal éventuel et fréquemment un cathéter urinaire. 
Un soutient médicamenteux hémodynamique, une antibiothérapie et /ou une sédation 
s’avèrent souvent nécessaires. Au début de leur séjour, ces patients présentent une 
phase de stress métabolique majeur et perdent rapidement du poids et de la masse 
musculaire. Le concept intuitif de support nutritionnel précoce permettant le maintient 
des défenses corporelles ainsi que la préservation des fonctions des différents organes 
a été largement étudiée et est admise bien que les évidences scientifiques manquent. 
Pourtant les supports nutritionnel et calorique sont souvent considérés comme non 
primordiaux et débutés plusieurs heures voire jours après l’admission. Cette attitude 
est également motivée par l’observation que la vidange gastrique peut être ralentie par 
différentes étiologies telles que ventilation mécanique, la défaillance circulatoire, les 
traitements médicamenteux incluant des opiacés, l’iléus post opératoire, les traumas 
neurologiques et les autres co-morbidités telles que la gastroparésie diabétique. Pour 
remédier à ces difficultés, il avait été préconisé dans les années 80 de débuter une 
alimentation parentérale. La preuve de l’efficacité de cette attitude thérapeutique n’a 
jamais été démontrée alors que les effets secondaires de l’alimentation parentérale 
sont observés quotidiennement. Pour cette raison un regain d’intérêt pour 
l’alimentation entérale est affirmé actuellement car il permettrait le maintient de la 
flore et de la muqueuse intestinale et éviterait les complications attribuables à 
l’alimentation administrée par voie parentérale telles qu’infections de cathéters, 
hyperglycémies, etc.…  
 
Différentes études ont été menées pour d’une part expliquer mais également essayer 
de corriger les altérations du transit intestinal. En particulier une, l’effet de 
l’administration d’un médicament qui augmente la vidange gastrique sur la tolérance 
de la nutrition entérale précoce chez des patients de soins intensifs soumis à une 
ventilation mécanique, a été étudiée par Spapen et coll. Cette étude prospective, 
randomisée et contrôlée a confirmé l’hypothèse des auteurs. L’absence 
d’administration de placebo et le protocole n’étant pas effectué en double aveugle, un 
biais de sélection ne peut être formellement exclu. 
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BUT DE L’ETUDE 
 
Nous avons conduit une étude similaire à celle de Spapen mais de manière 
randomisée-contrôlée en double aveugle afin de confirmer ou d’infirmer ses résultats. 
Les objectifs de l’étude étaient d’estimer la tolérance au support nutritionnel entéral 
mesurée par les résidus gastriques et la quantité journalière d’alimentation entérale 
administrée. 
 
 
MATERIEL ET METHODE 
 
De mai 1997 à mars 1999, nous avons enrôlé 34 patients de milieu de soins intensifs 
(Hôpital des Cadolles-Neuchatel, Soins Intensifs de Chirurgie-HUG) remplissant les 
critères d’éligibilités suivants : Ventilation mécanique débutée depuis moins de 24 
heures, absence de contre-indication à l’alimentation entérale et durée du support 
nutritionnel entéral estimée à 5 jours ou plus.  
 
Design de l’étude : 
 
Le support nutritionnel devait être initié durant les vingt quatre premières heures 
suivant le début de la ventilation mécanique via une sonde naso-gastrique de type 
Salem 14 Fr ou 16 Fr. Le positionnement correct de la sonde était établi initialement 
par un cliché radiologique puis vérifié deux fois par jour par l’inflation d’air et 
l’auscultation du bruit gastrique subséquent. 
Le protocole consistait en l’administration quatre fois par jour soit de 10 mg de 
cisapride ou de son placebo en double aveugle via la sonde naso-gastrique (cf. figure 
ci dessous ; T1-T3-T4-T6). Une nutrition entérale était débutée dès que possible en 
continu 11 heures sur 12 heures (T0 à T2) suivies de 1 heure de jeûne (T2 à T3), à 
répéter sur les 12 heures suivantes (T3 à T5 puis T5 à T6). La vidange gastrique était 
évaluée par aspiration au travers de la sonde naso-gastrique deux fois par jour suite à 
l’heure de jeûne (T3 et T6). Selon la quantité de résidu gastrique mesurée, la nutrition 
entérale était poursuivie ou stoppée selon un protocole prédéfini. Le cisapride ou son 
placebo étaient administrés après la mesure du résidu gastrique ainsi que 6 heures plus 
tard. 
 
 
 
T0  T1  T2  T3 T4          T5  T6
 0   6  11   12 18          23 24Heures: 
  
 
 
 
Temps: 
 
 
 
 
 
 
 
 
 
En cas d’intolérance à la vitesse d’administration de l’alimentation entérale (définie 
par un résidu gastrique supérieur à 250 mL), la solution de cisapride versus son 
placebo continuait d’être administrée aux temps prévus selon le protocole et les 
résidus gastriques notés. Si la nutrition entérale était redémarrée selon une nouvelle 
échelle de temps, les heures d’administration du cisapride et de son placebo étaient 
adaptées en fonction. 
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Etaient considérés comme intolérants à l’administration de nutrition entérale les 
patients présentant plus de 3 résidus gastriques supérieurs à 250 mL consécutifs et/ou 
des vomissements plus d’une fois par jour. Dans ce cas, un essai d’administration de 
cisapride 10 mg par voie non aveugle en maintenant le même protocole horaire était 
tenté. Dans le cas où ce test s’avérait inefficace, le patient était considéré comme 
intolérant à l’alimentation entérale précoce. 
 
L’étude était considérée comme terminée lorsque le support nutritionnel entéral était 
stoppé, que l’apport oral était repris ou que le patient était transféré hors de l’unité de 
soins intensifs où avait lieu l’étude. 
 
Les données collectées comportaient les caractéristiques démographiques des patients, 
leur évolution durant leur séjour ainsi que différents scores de gravités. Par ailleurs 
des tests de laboratoires usuels ainsi qu’un bilan azoté étaient effectués. Les apports 
caloriques et protéiques, ainsi que la quantité de nutrition entérale étaient relevés en 
plus des résultats des résidus gastriques, ainsi que la présence de nausées, 
vomissements ou diarrhées. Une gastroscopie était pratiquée dans la mesure du 
possible afin de confirmer la justesse de la mesure du résidu gastrique. Un cliché 
radiologique pratiqué lors de la mise en place de la sonde naso-gastrique n’était répété 
qu’en cas de suspicion de complication pulmonaire. 
 
Les résultats principaux étaient : 
• L’apport calorique journalier 
• La tolérance à l’alimentation entérale reflétée par les résidus gastriques, la 
présence de nausées, vomissements ou diarrhées. 
• La longueur du séjour en milieu intensif et en milieu hospitalier ainsi que 
l’évolution clinique. 
 
 
RESULTATS ET DISCUSSION 
 
Trente-deux patients ( 28 à Neuchâtel et 4 à Genève) furent recrutés consécutivement 
et randomisés pour recevoir en double aveugle soit du cisapride (n=16) ou son 
placebo (n=16). Les caractéristiques démographiques de ces patients (âge, sexe, 
scores SAPS II, SOFA, diagnostic d’admission, durée de séjour en milieu intensif et 
hospitalier ainsi que leur devenir) étaient similaires et les deux groupes étaient 
comparables. Le délai d’initiation du support nutritionnel entéral, la durée de ce 
support et la durée d’intubation oro-trachéale en raison de la ventilation mécanique 
étaient aussi similaires. L’intervalle entre l’admission et l’initiation de l’alimentation 
entérale était de 13 heures dans chaque groupe. Six patients ont été déclarés 
intolérants à l’alimentation entérale (3 dans chaque groupe) et ont nécessité une 
alimentation par voie parentérale.  
 
Effet du cisapride sur le résidu gastrique journalier: 
 
Les valeurs moyennes et médianes des résidus gastriques mesurés étaient de 71mL 
±23mL et 76mL (intervalle min-max: 33-99mL) respectivement dans le groupe 
cisapride et de 132mL ±36mL et 136mL (intervalle min-max : 70mL-181mL) 
respectivement dans le groupe placebo avec une valeur statistique de p<0.005. 
 
Résidu gastrique moyen au départ et durant les 6 jours suivants chez les patients 
randomisés à recevoir du cisapride (n=16) ou son placebo (n=16) (graphique # 1). 
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Effet de l’administration de cisapride sur l’apport entéral en terme de millilitres 
d’apport entéral (graphique # 3), de grammes de protéines (graphique # 4) et de 
calories (graphique # 5). 
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Comme les résidus gastriques étaient systématiquement réinjectés dans l’estomac via 
la sonde naso-gastrique exceptés si supérieurs à 250 ml, l’apport entéral   compte de la 
quantité d’apport entéral prescrite ajoutée au résidu gastrique réinjecté. Les données 
concernant l’apport protéique et calorique sont dérivées de l’apport entéral total par 
patient. Ni l’apport total entéral, ni l’apport protéique journalier ou l’apport calorique 
ne sont statistiquement différents entre les groupes de patients recevant du cisapride 
ou du placebo. 
 
 
Effet du cisapride sur les marqueurs biologiques de l’activité métabolique : 
 
La balance azotée mesurée chez 22 patients (11 dans chaque groupe) n’est pas 
différente de manière statistiquement significative (p=0.59), bien que les valeurs du 
bilan azoté soient moins négatives dans le groupe cisapride.  
L’apport calorique minimal a été atteint chez un petit nombre de patient et de manière 
similaire sans différence statistiquement significative entre les deux groupes : chez 
35% des patients après 3.8 jours respectivement dans le groupe cisapride et chez 25% 
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des patients après 4 jours en moyenne respectivement dans le groupe placebo 
(p=0.55). 
 
Finalement, aucune complication liée soit à l’alimentation entérale, excepté quelques 
cas de vomissements, soit à l’administration de cisapride (en particulier aucune 
arythmie sur le monitoring cardiaque continu) n’a été observée.  
 
 
CONCLUSION 
 
Cette étude montre que si le cisapride est ajouté à un protocole de nutrition entérale 
chez des patients de soins intensifs soumis à une ventilation mécanique, la vidange 
gastrique est doublée. La tolérance à la nutrition entérale, reflétée par les résidus 
gastriques aspirés, est améliorée par l’administration de cisapride, ceci sans effet 
secondaire. D’autre part l’observance stricte d’un protocole d’alimentation entérale 
pré-défini est nécessaire au succès de ce type de support nutritionnel et permet de 
compenser le retard de vidange gastrique en termes de calories. Le délai 
d’introduction du support nutritionnel entéral peut par ailleurs être réduit si un 
protocole strict est appliqué. 
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SUMMARY 
 
The present medical thesis revisited the gastro-intestinal physiology and 
pathophysiology before focusing on nutrition treatment in critically ill patients. In the 
second part a study aim at improving nutritional status was conducted and analyzed. 
 
Critically ill, mechanically ventilated patients admitted to the Intensive Care Units for 
medical or surgical problems often present comorbidity in parallel of their main 
admission diagnosis. The former includes the nutritional and immune status before the 
admission, cardio-vascular, respiratory and metabolic disorders and their 
repercussions. Moreover, admission in the Intensive Care Unit implies an invasive 
management of the patient with intra-vascular accesses, intra-tracheal tube impairing 
coughing, and urinary catheter, eventually a vaosactive or inotropic support, an 
antibiotic therapy and/or a medical sedation. Nutritional support is often considered of 
lower priority than vital support and only begun after several hours or even days after 
admission. This, even though patients experience metabolic stresses and rapidly lose 
body weight and muscle mass. Early nutrition may also be delayed because of 
impaired gastric emptying resulting from various etiologies. 
 
It is now well recognized that enteral nutritional support is better than parenteral 
nutrition. To improve it’s tolerance, Spapen et al designed a prospective randomized 
controlled study to investigate the effect of cisapride on tolerance to early enteral 
nutrition assessed by gastric emptying measurement in critically-ill, mechanically 
ventilated patients. They showed an improvement in the gastric emptying. However, 
the study design was not optimal (absence of blinding, no placebo). We decided to 
conduct a similar study in a double blind-randomized controlled manner in order to 
confirm or refute their results.  
 
We enrolled thirty-four critically ill, mechanically ventilated patients who received 
either 10 mg of cisapride or its matched placebo via a naso-gastric tube four times a 
day. Enteral nutrition was started as early as possible after admission and gastric 
emptying was evaluated by gastric aspiration through the naso-gastric tube twice a 
day.  
 
The conclusion of the study was that if cisapride is added to a standard enteral feeding 
protocol, gastric emptying is doubled and tolerance to an early enteral nutrition 
reflected by the gastric aspirate is improved. Finally, this improvement was observed 
without secondary effects. 
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INTRODUCTION 
 
1. Review of the physiology of the transit of the gastrointestinal tract 
 
The gastrointestinal system is a boundary between the external and the internal 
environments. Indeed, the food is prepared for passage to the internal environment 
through the stomach by digestion (nutrients are broken into smaller units) and 
absorption through the intestinal mucous membrane. 
 
1.1: Motor function of the gastrointestinal tract 
The gastrointestinal transit results from two types of movement: mixing and 
propulsion or peristaltic movements. It moves forward the alimentary bowl at a rate 
appropriate to digestion and absorption along the intestine. Myenteric plexus, 
stimulated and modulated by the parasympathetic system, promotes the departure, 
intensity and rate of the bowel movements. Atropine, a anticholinergic drug, removes 
the totality of the nerve impulse and paralyzes the myenteric plexus.  
 
Swallowing of the alimentary bowl is a reflex that transfers the chewed food from the 
mouth to the esophagus. A swallowing movement is made of three parts: a first part: 
voluntary, who initialized the process; a second part: pharyngeal, involuntary, which 
transfers the alimentary bowl from the pharynx to the esophagus; and a third part, 
involuntary, which allows the food to go from the esophagus to the stomach.  
 
1.1.1: Stomach 
The proximal stomach presents two types of bowel movement: primary, reflex to the 
peristaltic movement of the esophagus and secondary, resulting from distension of the 
esophagus, which still contains part of alimentary bowl. These movements are under 
control of the parasympathetic system and are initiated by a relaxation of the whole 
stomach and the gastro-esophageal sphincter. The main role of this sphincter, located 
at the junction between the esophagus and the stomach (five last cm), is to prevent 
regurgitation of the gastric bowl in the esophagus by tonic contraction of the lower 
part of the esophagus (circular muscle). A vagal reflex secondary to the increased 
intragastric pressure reinforces this tonic contraction. 
 
Anatomy of the stomach 
 
(See Fig. #1) 
 
Illustration found on the Internet: Stomach 
anatomy 
 
 
The stomach can be divided into two functional compartments. The proximal part 
(fundus and upper body) where food is stored and the distal stomach (lower body and 
antrum). The distal part is primarily responsible for the mixing and breakdown of 
solids that are transformed into chyme and then slowly evacuated in the small 
intestine. The evacuation rate is determined by the quality (osmolality, type of fatty 
acids, proteins or polypeptides) [1] and type of food ingested (liquid or solid), and by 
the degree of activity of the peristaltic impulse starting from the antrum, and 
spreading to the pylorus and the duodenum (relaxing-reflex of the sphincter of the 
pylorus and the proximal duodenum). The emptying of liquid from the stomach is 
function of the pressure gradient between the stomach and the duodenum. The 
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stomach dilation by the bowl produces an increase of the rate of chyme evacuation 
(vagal-reflex stimulated by distension of the wall). 
Two types of contraction in the proximal stomach are observed: slow sustained 
contractions and, superimposed on these, more rapid, phasic contractions. 
 
Motor activity of proximal stomach responsible for gastric emptying 
 
 
(See Fig #2) 
 
  Adapted from [2] 
 
The sustained contractions are responsible for the basal pressure within the stomach. 
Deglutition and gastric distension will result in prompt relaxation of the proximal 
gastric wall by inhibition of the sustained contractions. This receptive and adaptive 
relaxation permits the fundus and upper body of the stomach to act as a reservoir 
while maintaining low intragastric pressures. Inhibitory vagal neurons, which are 
noncholinergic, nonadrenergic and partially dopaminergic mediate this reflex.  
 
The stomach contains pacesetter cells located in the smooth muscle cells in the upper 
body of the stomach on the greater curvature. This gastric pacemaker generates slow 
cyclic depolarizations, which are propagated distally to the pylorus. A basal activity 
of 3 to 4 cycles per minute is observed. Superimpose are more vigorous peristaltic 
waves which are generated by excitatory stimuli such as neurotransmitters.  
 
Electrical and motor activity of distal stomach responsible for gastric emptying of 
digestible solids 
 
(See Fig #3) 
 
  Adapted from [2] 
 
 
The muscular contraction results in circular rings, which increase in amplitude and 
velocity as they move distally. During the postprandial state, rhythmic sets of 
peristaltic waves that constitute the digestive pattern of the distal stomach are 
observed. These contractions have two functions: first to transport, and second a 
mixing and grinding effect on solid foods. As the peristaltic wave approaches the 
distal antrum, the terminal antrum and pylorus close. Large solid particles retained in 
the stomach by the antropyloric closure are retropelled and triturated in the antrum. 
Through this grinding action, along with acid-peptic digestion, most solid particles are 
reduced to chymous-like consistency, allowing outflow into the duodenum. As with 
the proximal stomach, the distal stomach is controlled via both neural (vagal and 
sympathetic fibers) and hormonal mechanisms: gastrin increases the frequency of the 
gastric pacemaker and facilitates generation of action potential, its net effect is to slow 
down gastric emptying.  
 
Solids that cannot be broken (>2.0mm) are eliminated from the stomach by a different 
mechanism: the migrating motor complex (MMC). This interdigestive myoelectric 
complex, which recurs approximately every 2-h and takes place during the fasting 
state, begins in the proximal stomach and migrates aborally through the small bowel. 
It is composed of four phases. Phase 1: a period of motor inactivity lasting 45-60mn. 
During phase 2, there are intermittent peristaltic contractions that increase in 
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frequency and amplitude over a 30-45mn period. In the 5-15mn periods, designated as 
phase 3, there is a salvo of peristaltic contractions (3 per minute) generated by action 
potentials occurring with every pacesetter potential. In the fasting state, the pylorus 
remains open as phase 3 interdigestive contraction approaches and the contraction 
sweeps indigestible solids out of the stomach. Phase 4 is a short transition period 
between the electromechanical surge of phase 3 and the inactivity of phase 1.  
 
Motor activity responsible for gastric emptying of indigestible solids 
 
(See Fig #4) 
 
  Adapted from [2] 
 
These interdigestive cycles are switched off by neural and hormonal mediators: the 
periodicity is thought to be determined by signals from the central nervous system, 
Motilin plays an initiating role, truncal vagotomy delays the onset of a pattern of 
gastric contractions and gastrin inhibits fasting electromechanical cycles. Virtually 
any peptide, hormone or transmitter substance in the gut is involved in the regulation 
of fasting motility [3]. Animal studies have shown that inhibitors of nitric oxide 
synthase (NOS) initiate premature phase IIIs of the MMC, whereas donors of nitric 
oxide (NO) disrupt the MMC. Russo et al, [4], in there work used an inhibitor of NOS 
in healthy human volunteers. Their study confirms that NO mechanisms play a role in 
the regulation of fasting small intestinal motor activity in humans. 
 
1.1.2: Small intestine 
 
Illustration of small intestine cells 
 
(See Fig #5) 
 
Illustration found on the Internet: GI Tract 
Anatomy and Morphology of the Small 
Intestine  
 
The small bowel, where most of the absorption of the digested food takes place, 
contains receptors, which inhibits gastric emptying, when stimulated via neural and/or 
hormonal pathway. Gastrin, cholecystokinin, GIP-gastric inhibitory polypeptide, 
secretin, glucagon, VIP-vasoactive intestinal polypeptide and somatostatin mediate 
the hormonal pathways.  
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List of hormones acting on the physiology of the gastrointestinal tract: 
 
Hormone Produced by Major function (s) 
Gastrin Gastric antrum 
Duodenum 
Acid secretion, contraction of the 
gastro-esophageal sphincter, secretion 
of glucagon 
Secretin Mucosa Pancreatic secretion of water and 
electrolytes 
Cholecystokinin Mucosa Gall bladder and pancreatic secretion 
GIP Mucosa Inhibits gastric acid secretion 
Motilin Mucosa Contraction of gastro-esophageal 
sphincter 
Substance P Mucosa 
Nerves 
Unknown 
Somatostatin Gastric antrum 
Pancreatic δ cells 
Endocrine/paracrine; inhibits 
secretion of gastrin, secretin, GIP, 
motilin, pancreatic secretion, 
glucagon, insulin 
VIP Nerve cells 
Endocrine cells 
Pancreatic secretion 
Glucagon Pancreatic α cells Stimulates release of insulin and 
pancreatic somatostatin 
Insulin Pancreatic β cells Anabolic hormone 
   
  Adapted from [5] 
 
The different receptors include acid receptors (proximal duodenum and jejunum), 
osmotic receptors sensitive to electrolytes, carbohydrates and amino acids except for 
L-tryptophan (duodenum), and L-tryptophan receptors (all portion of duodenum and 
jejunum). Increasing osmolarity of solution results in slower gastric emptying, 
although some hypoosmolar solutions may also inhibit elimination. Fatty acids, 
monoglycerides and diglycerides delay gastric emptying. The emptying of 
carbohydrates and amino acids, except for L-tryptophan (which always delays gastric 
emptying), is determined by the osmolality of the solution via the osmoreceptors.  
 
The propagation of the chyme in the small intestine is simpler than in the stomach, as 
the walls of the duodenum, jejunum and ileum have three muscular layers to help 
churn, mix and propel. A peristaltic reflex is initiated by distension of the walls as 
soon as the nutrients passe through the intestine. 
 
Physiology of gastric and small intestine emptying 
 
(See Fig #6) 
 
  Adapted from [2] 
 
 
1.1.3: Large intestine 
In the large intestine, final absorption of electrolytes and water takes place. The 
remaining content at the end of the large intestine is the feces, which is stored until 
exoneration takes place. The movements of the layer are relatively slow, but resemble 
that of the small intestine (mixing and propulsion). Defecation starts when the bowl 
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arrives in the rectum, with reflex contraction of the rectum and relaxation of the anal 
sphincters; it is stopped until voluntary relaxing of the external anal sphincter takes 
place. 
 
The propulsive movements appears after meal and are partially related to the gastro-
colic reflex and duodeno-colic reflex coming from distension of the stomach and 
duodenum. Transmission is made through the myenteric plexus and the 
parasympathetic system [2, 6]. 
 
1.2: Bacterial population of the Gut 
Gastrointestinal motility is also a major, natural defense mechanism against infection 
of the gut [7]. Microorganisms are relatively scarce in the esophagus, stomach, 
duodenum and jejunum, due either to the basal condition of the “interior-milieu” 
(acidity) and to the migrating motor complexes, which periodically flush the luminal 
content of the proximal gut towards the colon. As movement of the intestinal contents 
slows in the terminal ileum, the quantity of bacteria rises tremendously [8]. In contrast 
to the stomach and small intestine, the contents of the colon teem with bacteria, 
predominantly strictly anaerobes. 
 
Bacterial Populations in the Digestive Tract of Normal Humans: 
 
 Stomach Jejunum Ileum Colon 
Viable bacteria 
per gram 
0-103 0-104 105-108 1010-1012 
pH 3.0 6.0-7.0 >7.5 6.8-7.3 
 
1.3: Secretory function of the Gut 
The whole gut contains secretory gland with specific function varying in each part. 
The two main functions are enzyme secretion (from the mouth to the terminal ileon) 
to make some nutrients soluble and participate to the digestion of macro-elements, 
and mucus secretion (from the mouth to the anus). Mucus contributes to mucosal 
defense by providing a physical barrier to bacteria, thereby reducing bacterial 
adherence to the epithelium and invasion of the mucosa. Mucus also acts as lubricant 
to reduce physical abrasion of the mucosa and participates to the protection of the 
mucosa from damage induced by acid and other luminal toxins. An increase in mucus 
thickness is a normal defensive response to luminal insult. Water and electrolytes are 
also secreted in the gut lumen. This fluid secretion reduces bacterial adherence, 
dilutes and flushes away any potential noxious substances in the lumen. Global 
secretion function help propel the digestive bolus along the digestive tract. 
 
In the stomach, the cardia contains glands, which secrete mucus. The body, which is 
the main secreting area, contains chief or pepsin secreting cells, parietal oxyntic cells, 
secreting HCl and intrinsic factor, and mucus cells in the duct. The pyloric part 
contains mainly mucus secreting cells. There are finally epithelial cells, which product 
small amounts of enzymes and watery secretions.  
 
The tubular glands, which product mucus in the small intestine and the colon, are the 
Lieberkühn glands. Other glands situated in the salivary glands, pancreas and liver, 
product the secretions necessary for digestion and emulsification of nutrients. The 
salivary and pancreatic glands are acinus glands.  
 
Beside mucus secretion, gut cells secretion is initiated by several stimuli such as 
presence of food or chemical irritation, distension of the gut wall, increase in gut 
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motility, parasympathetic stimulation and hormonal regulation (nutriments in the gut 
lumen promote gastro-intestinal hormones secretion as mentioned above). Mucus 
secretion is permanent, but nitric oxide (NO) is an important regulator of mucus 
quality and quantity secretion in the stomach (stimulation of guanylyl-cyclase in the 
epithelial cell) [9]. NO seems also to play an important role in the modulation of 
epithelial fluid secretion. The latter, is also osmotically driven by the active transport 
of chloride ions into the lumen [9]. 
 
The resulting total volume of daily gut secretion is of 7200mL (saliva: >1500mL, 
gastric secretion: 2000mL, pancreatic secretion: 1200mL, biliary secretion: 700mL, 
intestinal secretion: 2000mL and colic secretion: 100mL). The ingested fluid is about 
1500mL per day. More than 7000mL are then absorbed in the small intestine and 
normally 500ml leaves the small intestine and enters the colon [6].  
 
1.4: Immune function of the Gut  
Immune function of the gut has only been observed in animal studies. Conclusions are 
extrapolated to human, without clinical trials. 
 
Several mechanisms protect the mucosal cell from potential pathogens, preventing 
invasive infection and bacterial access into the systemic circulation. Mucus 
production (direct mechanical surface protection), gastric acidity and intact 
peristaltism prevent bacteria from penetrating the mucosal cell and producing sepsis. 
If microorganisms are able to penetrate through the mucus and fluid secreted by the 
epithelium; the tight junction between adjacent epithelial cells forms the next barrier 
they encounter. This junction is regulated by NO [9]. 
 
The gastrointestinal tract contains also an immune tissue: the GALT (Gut-Associated 
Lymphoid Tissue). This tissue is located in the mucosal layer along the gastro-
intestinal tract (diffuse isolated cells) and forms Peyer’s patches under the mucosal 
layer in the distal part of the small intestine. This tissue contains 70 to 80% of all 
immunoglobulin-secreting cells of the body [10]. IgA, the primary immunologic 
product of this system, is a critical component of mucosal immunity and barrier 
integrity and accounts for 50% of the body’s total immunoglobulin production. IgA 
are secreted from IgA+ plasma cells after sensitization in the Peyer’s patches and are 
homed into the lamina propria. The IgA produced in the lamina propria are 
immediately transported by means of mucosal epithelial cells by secretory 
components onto the mucosal surface [11].  
 
Secretory IgA (S-IgA), of which ninety percent are secreted in bile, intestinal 
secretion, saliva, tears and breast milk, prevents adherence of bacteria, viruses, and 
enterotoxins to the mucosal surfaces (intestinal microvilli). They also prevent the 
uptake of enteric antigens and may play a role in eliminating infectious agents that 
have penetrated epithelial cell layers [11, 12]. Intestinal secretory-IgA levels 
correlates inversely with bacterial overgrowth, bacterial translocation, and changes in 
intestinal permeability in animal models [13]. 
 
 
Illustration of stimulation and homing of S-IgA 
 
(See Fig #7) 
 
  Adapted from [12] 
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A reduction in the luminal level of secretory-Ig A (as seen in case of exclusive 
parenteral nutrition) results in a greater frequency of gastrointestinal microorganism 
proliferation and, coupled with impaired reticuloendothelial function often seen in 
critically ill patients, may predispose to systemic bacteremia. The feeding of an oral 
diet appears to be especially important for the maintenance of secretory-IgA antigenic 
stimulation of the intestine [11, 12]. 
 
2. Assessment of gastric emptying in normal and pathological conditions  
 
The general methods currently used in evaluating gastric emptying are intubative 
techniques (gastric or duodenal intubation, with or without marker), imaging 
techniques (radiological: liquid barium sulfate or radiopaque meals; scintigraphy; 
ultrasonography; MRI), and indirect absorption techniques (blood tests, breath tests).  
 
The intubative techniques have provided valuable information regarding emptying of 
solid and liquid meals in various disease states. But they are largely abandoned in 
clinical practice because of inaccuracy and invasiveness. Furthermore, gastric 
aspiration studies measure only liquid emptying, and the result may vary secondary to 
the position of the tube tip.  
 
Radiological techniques are considered unsatisfactory for use in gastric emptying 
studies. Although, duodenal dye dilution techniques are excellent as research tools, 
they require time and expertise [14]. Scintigraphy remains the most reliable method to 
measure gastric emptying [15]. Ultrasonography is able to demonstrate 
antropyloroduodenal motility and flow contents. In particular, 3-D ultrasonography is 
able to estimate gastric volume, and secondary gastric emptying rate (correlates only 
with liquid emptying) and duplex technique measure transpyloric flow. But these 
techniques rely on the experience of the performer [14, 16, 17]. Gastric emptying 
curves of liquid meals obtained with MRI correlate very well with scintigraphic 
curves [18]. But this rather new technique is expensive and cannot be performed at the 
bedside [17]. 
 
Indirect techniques to measure gastric emptying include the paracetamol (or 
acetaminophen) absorption test and 13C breath tests. Paracetamol test is frequently 
used to measure gastric emptying of liquids. It is based upon pharmacokinetic 
evidence that paracetamol in solution is not absorbed in the stomach but is rapidly 
absorbed from the small intestine after passage through the pylorus [19, 20]. A fixed 
dose of paracetamol is given orally at T0, through the naso-gastric tube. Arterial blood 
samples are taken before the administration of paracetamol and then at repeated 
intervals, during six hours after administration. Paracetamol concentrations in blood 
samples are then measured to determine the area under the paracetamol absorption 
curve, the time to peak paracetamol plasma concentration and the peak paracetamol 
concentration [21, 22]. But there is no correlation between paracetamol absorption 
and volumes of gastric aspirates [23]. 13C breath tests (13C acetate [24] or 13C 
octaonate [25]) can measure the gastric emptying of liquids and solids respectively 
and can achieve accuracy comparable with gastric scintigraphy.  
 
Correlation between gastric emptying and the volume of gastric aspirate or the 
presence of bowel sounds has not been proved and is questioned [26]. But it is 
generally admitted that a gastric residue lower than 120 to 150mL correlate with a 
satisfactory gastric emptying. However, Cohen et al, [27], showed that paracetamol 
absorption test may be normal in patients with relatively high gastric residual volumes 
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(more than 150mL after 8 hours, or more than twice the hourly infusion rate in that 
study of critically ill patients). 
 
3. Delayed gastric emptying: etiology, prevalence, symptoms and pathophysiology 
 
Delayed gastric emptying states can result from many factors: mechanical, metabolic 
and endocrine, gastric disease, post-gastric surgery, medications and idiopathic origin.  
 
3.1: Etiology 
The delayed gastric emptying can be transient or chronic.  
 
 Transient delayed gastric 
emptying 
Chronic delayed gastric 
emptying 
Mechanical factors Mechanical ventilation Gastric carcinoma and tumor 
associated, pyloric or 
prepyloric ulcers, idiopathic 
hypertrophic pyloric 
stenosis, pseudo-obstruction 
resulting from amyloidosis, 
muscular dystrophies, 
dermatomyositis, 
sclerodermia 
Gastric diseases Viral gastroenteritis Gastroesophageal reflux, 
gastric ulcer disease, 
atrophic gastritis ± 
pernicious anemia 
Metabolic and 
endocrine origin 
Acute diabetic ketoacidosis, 
pregnancy 
Diabetes mellitus,  
Anorexie nervosa? Bulimia 
nervosa? 
Post gastric surgery Postoperative gastro-colo 
paresis 
Post vagotomy and/or post 
gastric resection 
Medications Morphine, anticholinergics, 
levodopa, β-adrenergic 
agonists, L-dopa 
Hormones in pharmacological 
studies: gastrin, 
cholecystokinin, somatostatin 
dopamine 
Cigarette smoking 
Idiopathic origin  Idiopathic, idiopathic 
autonomic degeneration, 
chronic idiopathic intestinal 
pseudo-obstruction, gastric 
dysrhythmias-tachygastria, 
gastroduodenal 
dyssynchrony 
Central nervous 
system origin 
 Spinal cord injury, brain 
stem lesions and traumatic 
brain injury, Parkinson’s 
disease, depression? 
Electrolytes 
abnormalities 
Hypokalemia, hyperglycemia, 
hypercalcemia, hypocalcemia, 
hypomagnesemia 
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3.2: Prevalence 
The reported prevalence of delayed gastric emptying varies between studies. For 
diabetes mellitus it varies from 22% to 50% (whether insulin dependent or non-insulin 
dependent); for gastroesophageal reflux, solid food retention can be seen in 57% of 
patients, whereas 38% have normal emptying of solids and 5% displayed rapid 
emptying.  
 
3.3: Symptoms 
Many patients with grossly delayed gastric emptying have few or no symptoms. 
Delayed and more rapid gastric emptying may also result in similar symptoms.  
 
Clinical manifestations of gastric emptying disorders include nausea, vomiting, 
abdominal discomfort, early satiety, “dumping” and diarrhea. Posprandial symptoms 
are usually worse, but symptoms may also be delayed. Moreover, esophageal, small 
intestinal, colonic and anorectal motor dysfunction are often associated with 
disordered gastric emptying. Thus, dysphagia, diarrhea, constipation and fecal 
incontinence are observed [2, 28].  
 
3.4: Pathophysiology 
Pathophysiologic mechanisms of delayed gastric emptying include defective pumping 
through weak contraction and abnormally high resistance to emptying.  
 
Subnormal fundic tones, weak or absent antral pumping contractions and proximal 
duodenal retention because of duodenal pump failure, are causes of defective 
pumping through weak contractions.  
 
Abnormally high resistance to emptying is due to persistently obstructive or 
retropulsive contractions of antrum and pylorus, excessively frequent localized 
pyloric contractions-pylorospasm and obstructive patterns of duodenal contraction. 
The preponderance of nonexplusive antral contractions (antral phase 3 activity is 
absent) is found in case of idiopathic gastroparesis. In case of diabetes mellitus, 
marked antral hypomotility (abnormal gastric pacemaker function) and a 
preponderance of nonexplusive antral contractions (same mechanism as in case of 
gastroparesis) have been demonstrated. Gastric surgery produces transient or 
permanent impairments of the ability of the stomach to grind solid food, to retain it 
within the stomach and to pump meals into the duodenum. In only a minority of 
patients these anatomical modifications cause majors symptoms due to delayed gastric 
emptying, more rapid emptying of liquids and/or alkaline reflux gastritis [28].  
 
3.4.1 Delayed gastric emptying following traumatic brain injury 
In case of traumatic brain injury, difficulties in feeding and poor tolerance to gastro-
enteral feeding are often observed [29]. They are either due to a hypermetabolic state, 
which appears immediately after trauma, or to swallowing disorders that frequently 
follow acute brain injury, or are secondary to gastroparesis. This poor tolerance may 
persist from 14 days until 4 to 6 months after brain injury [30]. At the beginning, a 
significant inverse relation ship is observed between daily intracranial peak pressure 
and time to tolerance of feeding [31]. Similar findings have been described by Garrick 
et al. [32], who demonstrated that gastric motility is inhibited and amplitude of gastric 
and duodenal contractions are reduced by over 80% and 60% respectively, by 
increased intracerebroventricular pressure in a rabbit model. This effect is of rapid 
onset and is reversed by a cholinergic agonist, suggesting a neural mechanism 
involving vagal inhibitory pathways. In human, the relative intolerance to enteral/oral 
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nutrition has been attributed to prolonged paralytic ileus, abdominal distension, 
aspiration pneumonia and diarrhea [33, 34], and an adverse effect of elevated 
intracranial pressure above 20 mmHg is suggested [31]. Saxe et al. [35] showed that 
lower esophageal sphincter dysfunction accompanies acute head injury and disappears 
if the Glasgow Coma Scale (GCS) is over 12. After spinal cord injury patients present 
also significant prolonged gastric emptying of solid meal in case of high-level injury 
(quadriplegic) [36]. 
 
3.4.2 Delayed gastric emptying due to medications 
Morphine and other opiate analgesics are notorious for causing gastric retention. 
Exogenous and endogenous opiates exert their influence directly on gastrointestinal 
receptors (opiates µ receptors) and via the central nervous system [2]. They are first 
associated with an increase in amplitude of gastric contractions, which is then 
followed by a prolonged decrease in gastric propulsive activity. The influence of the 
central nervous system has been questioned. Indeed, Murphy et al. [37] showed in 
their study that the use of methylnaltrexone (a quaternary derivative of the opiate 
antagonist naltrexone, which does not cross the blood-brain barrier) attenuates the 
morphine–induce delay in gastric emptying. Methylnaltrexone had the potential to 
decrease the side effects of opioid medications, which are mediated peripherally, 
while maintaining the central analgesia effect of the opioid. Even small dose of 
morphine, such as 0.05mg/kg, which is already effective to produce analgesia, inhibits 
gastric emptying in human healthy volunteers, compared to placebo [38].  
 
β-Adrenergic agonists, such as isoproterenol and salbutamol, have been shown to 
delay gastric emptying, and propranolol was shown to reverse the action of 
isoproterenol. Propranolol, by-itself, was found to accelerate gastric emptying 
significantly. This suggests that under physiologic conditions, there may be β-
adrenergic inhibition of gastric activity [2]. 
 
Dopamine is known to decrease gastric tone. Moreover, it also increases the motility 
of the proximal part of the small intestine in humans [39]. However, delayed gastric 
emptying is universally observed. At a dose of 2 µg/kg/min, it produces a transient 
fall in gastric pressure in all healthy humans, and a persistent fall in some. At 8 
µg/kg/min, it reduces intragastric pressure and delay gastric emptying. The probable 
explanation is that dopamine produces β-adrenergic stimulation. Levein et al. [40] 
studied the effect of a continuous infusion of dopamine (5 µg/kg/min) on gastric 
emptying and oro-caecal transit time in human healthy volunteers. They showed that 
dopamine delays gastric emptying and prolongs oro-caecal transit time. It must be 
highlight that dopamine agonists have however plexiform effects on the digestive 
tract. For example the process of adaptive relaxation, whereby the stomach relaxes to 
receive a bolus of food, is mediated by the vagus nerve with dopamine as 
neurotransmitter [41].  
 
4. Treatment of delayed gastric emptying in critically ill patients 
 
Before prescribing drugs, simple methods to facilitate the gastric emptying must be 
used. First, semi-recumbent position is advantageous to diminish gastroesophageal 
reflux (GER). Avoiding supine position prevents some regurgitation by gravity. 
Indeed, if the head is not maintained above the abdomen, the gastric content will 
always have a tendency to flow back in the mouth. 30% of patient kept in supine 
position are estimated to have GER even in the absence of a naso-gastric tube. The 
naso-gastric tube also predispose the patient to reflux by interfering with the lower 
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esophageal sphincter function, as well as prolonging esophageal contact time with 
refluxed gastric content [42]. Furthermore, avoiding a contact between nasogastric 
tubes and the pylorus may prevent pyloric hyper-contractions and thus gastric food 
retention. If these simple measures do not improve gastric emptying then 
pharmacological treatment may be prescribed.  
 
4.1: Review of the usual prokinetic drugs employed and of their efficiency in critically 
ill patients 
The most effective approach to treat gastroparesis is the use of drugs designed to 
increase the rate of gastric emptying by facilitating gastroduodenal motility. [43]. The 
gastrokinetic drugs available are:  
• Metoclopramide  
• Domperidone 
• Cisapride  
• Erythromycin 
Their gastrokinetic effect is due to direct dopamine receptor blockade (domperidone, 
metoclopramide), stimulation and blockade of subtypes of 5-hydroxytryptamine 
receptors (metoclopramide, cisapride) and stimulation of motilin receptors 
(erythromycin). Most of these effects appear to be modulated by the final common 
path of increased acetylcholine release at gastric neuromuscular junctions. All these 
drugs increase the amplitude of antral contractions [28]. Bethanechol, a 
cholinomimetic drug, increases the rate of gastric emptying and gastric motor activity 
in some patients with gastroparesis, but overall its clinical efficacy has been 
disappointing [43]. 
 
• Metoclopramide has both central and peripheral antidopaminergic properties. 
It releases acetylcholine from the myenteric plexus, without affecting gastric 
acid secretion. It also has central antiemetic properties. Its use is limited by 
neurological side effects (central antidopaminergic effects), such as anxiety, 
drowsiness and lassitude (up to 20% of patients); dystonic reactions occur in 
about 1%. Secondary hyperprolactinemia is also well known [28]. 
• Domperidone is a peripheral dopamine antagonist like metoclopramide, but 
lacks cholinergic activity. Neurologic side effects are rare, since it penetrates 
the blood-brain barrier poorly. Hyperprolactinemia occurs occasionally [28]. 
Domperidone is also believed to possess cardiac electrophysiological effects 
similar to those of cisapride and class III antiarrhytmic drugs [44]. 
• The next chapter will be allotted to cisapride. 
• Erythromycin stimulates gastrointestinal motility by acting as an agonist of 
receptors for the gastrointestinal peptide motilin, effect that is unrelated to its 
antibiotic properties [45]. The effect of erythromycin on gastric motor activity 
is dose-dependent [46]: small dose stimulates antral activity (phase III), which 
migrates into the duodenum, and higher dose induces strong contractions of 
the antrum, which are not propagated [47]. 
 
Effects on gastric motility of cisapride, erythromycin and metoclopramide are well 
studied in critically ill mechanically ventilated patients [48-51]. The study of Jooste et 
al. [49] shows that a single dose of metoclopramide improves gastric emptying 
(paracetamol absorption test). The benefit of such effect is however questioned. 
Indeed, Yavagal et al. [52] found no benefit after administration of metoclopramide 
on the prevention of aspiration pneumonia, mortality rate or the length of ICU stay in 
mechanically ventilated patients receiving enteral tube feeding. 
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The administration of erythromycin, which is also effective in improving gastric 
emptying in patients intolerant to nasogastric feeding [51], is followed by an increase 
in antral motility (manometric study) and an acceleration of gastric emptying 
(paracetamol absorption test) in the study of Dive et al. [48].  
 
The study of McLaren et al. [50] compares sequential single doses of cisapride, 
erythromycin and metoclopramide (paracetamol absorption test and gastric residual 
volumes) in critically ill patients intolerant to enteral feeding. They found that gastric 
residual volumes during the study are not significantly different between agents, and 
that metoclopramide or cisapride are effective for promoting gastric emptying. 
Metoclopramide seems to provide a quicker onset than cisapride. However, cisapride, 
which is as efficient as metoclopramide for gastric emptying, is more appropriate than 
the latter in critically ill patients, who need gastric emptying and stimulation of entire 
gut motility. Cisapride is also devoid of central effects. 
 
4.2: Focus on cisapride 
 
4.2.1 Pharmacokinetic aspects 
Cisapride, a substituted piperidinyl benzamide, can be administered via oral, 
parenteral or rectal way; only the oral formulation is authorized in Switzerland.  
 
Peak plasma concentrations of cisapride are achieved 1 to 2 hours after oral 
administration of a single 5 to 20 mg dose. The absolute bio-availability of the oral 
formulation of the drug is 40 to 50%. The volume of distribution is 2,4 l/kg and 
cisapride is 98% bound to plasma protein in vitro. Cisapride is metabolized in the 
hepatocytes (oxidative-N-dealkylation) and its major metabolite, norcisapride, has no 
pharmacological activity. The elimination half-life is about 7-10 hours in healthy 
volunteers (lengthened in patients with hepatic disease and some elderly subjects who 
can accumulate the drug). There is no evidence of significant alterations of its 
elimination in case of renal insufficiency. [53, 54].  
 
4.2.2: Pharmacodynamic aspects 
Mechanism of action: 
Cisapride stimulates gastrointestinal motor activity through an indirect mechanism 
involving the release of acetylcholine mediated by postganglionic nerve endings in the 
myenteric plexus of the gut [53]. The release of acetylcholine stimulates the gastric 
motility in a fashion similar to the natural progression of the interdigestive migrating 
motor complex. Cisapride also acts on serotonin receptors (serotonin = 5-
hydroxytryptamine = 5-HT). It is an agonist at the 5-HT4 receptor as well as 
antagonist at the 5-HT3 receptor. Studies indicate that the intestinal effect is most 
likely to result from activation of 5-HT4 receptors, although other, as yet unidentified 
serotonin receptors may also be involved [54]. The main site of action of cisapride in 
the stomach is supposed to be the proximal portion where the acceleration in gastric 
emptying occurs [55]. 
 
Efficiency on the different parts of the gut: 
Cisapride increases the lower esophageal sphincter pressure (LOSP) and esophageal 
motility by about 20 to 50% in healthy adult volunteers and patients with 
gastroesophageal reflux disease [54]. It also reduces the duration of esophageal pH<4 
[55]. It has been shown to reduce the exposure of the esophagus to gastric acid (effect 
attributed to the action on the LOSP, esophageal clearing peristalsis and gastric 
emptying). Its efficiency is similar or superior to metoclopramide in reducing 
esophageal exposure time to acid [53]. 
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In case of functional dyspepsia, the relief of symptoms is better with cisapride than a 
placebo [53], and similar to metoclopramide [54]. Patient suffering from functional 
dyspepsia compared to healthy volunteers, have delayed gastric emptying of solids, 
but not of liquids, when monitored by 13C breath tests. The use of cisapride 
significantly accelerates gastric emptying of solids, which remains still slower in case 
of functional dyspepsia. The effect of cisapride adjunction on gastric emptying of 
liquids is controversial: Duan et al. [56] found no modification, but a more recent 
study by Borovica et al. [57] found an acceleration of liquid gastric emptying. 
  
Cisapride enhances gastro-intestinal and colic motility [58]:  
• Comparative trials on the efficiency of cisapride with or without other active 
agents on gastroparesis are numerous and often contradictory or even non 
conclusive. The only conclusion one can draw is that cisapride efficiency is 
similar or superior to metoclopramide in reducing gastric transit time in healthy 
volunteers and in patients with idiopathic gastroparesis [53, 54]. Gastric emptying 
is accelerated in: 
o Healthy subjects and patients with idiopathic gastroparesis [53, 59, 60],  
o Gastroparesis associated with gastro-esophageal reflux disease [55],  
o Gastroparesis following surgery [61].  
The volume threshold required for antral stimulation is decreased.  
• Antro-duodenal motility and coordination are improved following single or 
multiple doses of cisapride in healthy volunteers and patient with dyspepsia 
(fasting and fed conditions) [53].  
• There are few trials evaluating the efficacy of cisapride on postoperative 
gastrointestinal atony. Wiseman et al. [54] in their review showed only an 
efficacy to relieve symptoms in case of Roux-en-Y gastro-jejunostomy. They 
found no efficacy to relieve nausea and vomiting in the early postoperative phase 
compared to a placebo. In case of cholecystectomy, Tollesson et al. [61], who 
studied the postoperative colonic motility, found that cisapride induced a 
significantly earlier return of propulsive motility in the right colon. An earlier 
first passage of feces occurred in the cisapride group (significant result). 
• In pharmacodynamic studies, cisapride restored colonic propulsive action and 
accelerated colonic transit in the caecum and ascending colon. Cisapride enhance 
the propagative motility of the colon (clinical trial) [61], reduce the transit time 
through the small and large intestine in healthy volunteers and patients with 
deficiencies in propulsive activity (diabetic autonomic neuropathy, quadriplegic 
patients) and cause a significant increase in stool frequency compared with both 
baseline and placebo [53, 62]. In a study on colonic transit time, the number of 
bowel movements increased in healthy volunteers and in patients with 
constipation [54]. 
 
Cisapride also has an effect on gallbladder volume (small reduction of volume 
followed by a faster refilling) compared to placebo [63].  
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Efficiency in case of opiate administration, diabetes mellitus: 
Opioid, such as morphine, are known to delay the emptying of the stomach and the 
absorption of the orally given drugs. The administration of cisapride (10 mg 
minimum) prevents the delay in gastric emptying (assessed using the rate of 
absorption of orally administered paracetamol) secondary to the administration of 
morphine [64]. In case of administration of morphine in a patient presenting a post-
operative paralytic ileus, the administration of cisapride induces earlier return of 
propagative motility [61]. 
 
Diabetes mellitus is known to cause neuropathy and in particularly, diabetic 
dysautonomia. It includes orthostatic hypotension, baseline tachycardia, cystopathy 
with urinary troubles, gastroparesis, diarrhea, sudation problems and so on. Cisapride 
is known to accelerate gastric emptying [59, 65, 66] and antroduodenal coordination 
[53] in case of diabetic gastroparesis. Borovica et al. [57] studied the effect of 
cisapride in diabetic patients with magnetic resonance imaging. They found no change 
in antral contractility following cisapride administration, but an acceleration of liquid 
gastric emptying that may be related to changes in proximal gastric tone or gastric 
outlet resistance.  
 
Secondary effects: 
Concentration of gastrin, insulin, glucose and prolactine do not appear to be altered by 
the drug. Metabolic control of insulin-dependant diabetes remains unaltered or 
improves during cisapride therapy [65]. There is an absence of central nervous system 
depressant effect, such as somnolence or fatigue compared to metoclopramide; and 
cisapride is devoid of antidopaminergic effects [53]. 
 
Cisapride is well tolerated in clinical trials. Side effects, such as transient abdominal 
cramping, borborygmi and diarrhoea or loose stools, which occurs infrequently, are an 
extension of its pharmacological action. They have only rarely necessitated treatment 
withdrawal [53, 67]. Verlinden et al. [68] in their review of 42 clinical trials, found a 
similar incidence of adverse events reported during cisapride treatment (13.7%) 
compared to placebo administration (11.2%). They found no evidence of any effect of 
cisapride on the cardiovascular system or on psychomotor function, no 
neuroendocrine (antidopaminergic like) effects (e.g. prolactine release, 
extrapyramidal reaction) and no effect on body weight. CNS effects such as 
somnolence or fatigue arise rarely (1,5%). No clinically significant changes in 
haematology or blood chemistry are to be found. 
 
Cisapride itself has no cardiac effects if used following recommendations, and 
specially avoiding drug interactions. Inman et al. [69] reviewed 13’233 patients 
treated with cisapride and 240’381 patients treated under substantially identical 
conditions without cisapride. They found that the rate of palpitations, tachycardia and 
extrasystoles recorded during the first month of prescription was 0.8 per 1000 for 
cisapride compared with a mean rate of 2.5 per1000 in the other patients. They 
conclude that these events might be coincidental. An effect of the drug on heart rate is 
not to be expected from its pharmacology (see next paragraph). There is a controversy 
on spontaneous reports of QT interval prolongation associated with the use of 
cisapride alone at any dose. For the Committee on safety of medicines and Medicines 
control agency, none are known [70], but in the literature, case reports are not rare 
relating long QT syndrome [71] or torsade de pointe [72]. 
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Directions for use: 
The recommended dosage in case of gastroparesis or gastro-esophageal reflux disease 
is 4 times daily 10 mg, 15 to 30 minutes prior to a meal (the presence of food enhance 
absorption of cisapride) [53, 60]. 
 
 
4.2.3: Drug interactions 
Drug interactions result from different mechanisms such as acting on the absorption 
rate, link to plasmatic proteins, hepatic metabolism (clearly the most important), 
hepatic and renal clearance and elimination.  
 
Cisapride increases, via his prokinetic effect, the absorption rate and thus the 
bioavailability of benzodiazepins, acenocoumarol, morphine [73], ranitidine, and 
cimetidine [74-76] when given concomitantly by oral route.  
 
Cisapride interacts directly with drug metabolised by the cytochrome P450 3A4 such 
as erythromycin, clarithromycin, fluconazole, itraconazole, ketoconazole and 
miconazole. These drugs, which inhibit its metabolism (ketoconazole inhibits directly 
the cytochrome P450 3A4), can enhance the plasmatic rate of cisapride. A high 
plasmatic rate of cisapride can then promote arrhythmia (report of 2 fatal case of QT 
prolongation, torsade de pointe and/or ventricular fibrillation) [70, 72, 77]. The exact 
mechanism of cardio toxicity is unknown but a procainamide-like effect has been 
suspected as well as an activation of 5HT-4 like receptors [78]. 
 
4.3:Administration of cisapride to critically ill patients  
 
Traumatic brain injury is often complicated by gastroparesis, which responds to 
metoclopramide therapy [34]. If not, the introduction of cisapride is followed by a net 
improvement in gastric tolerance [79]. 
 
Spapen et al. [80] studied the effect of adding cisapride to a standard enteral feeding 
on the gastric emptying in critically ill sedated and mechanically ventilated patient. 
Their results show that gastric emptying is significantly improved by adding 
cisapride. Furthermore two other studies from Heyland et al. [26, 81]and Goldhill et 
al. [26, 81] made the same conclusion with similar patients[26, 81].  
 
5. Nutrition of the critically ill patient 
 
The association between a poor nutritional status and a poor clinical outcome 
(mortality, morbidity, cost or duration of hospitalization) is well known. Since the 
1960s, it is possible to provide a systematic enteral or parenteral nutritional support to 
patients not able to eat or who lose weight.  
 
Critically ill patients are endangered to several failures including cardio-circulatory, 
respiratory, immune and nutritional failures during their stay in Intensive Care Unit 
(ICU)[82]. Some patients may experience shock state before admission to ICU, which 
can produce mucosal injury. Furthermore, an immunocompromised state is often 
observed, especially following surgery. Drug treatment and/or dietary regimens that 
are administrated are also both able to disrupt the normal ecology of the gut flora. 
Deitch et al. studied rats [83] and confirmed their hypothesis that permeability of 
intestinal mucosa exist when shock and absence of nutrition is simultaneously present. 
They extrapolated conclusions to critically ill patients from the animal model:  they 
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suggested that the rupture of the normal ecology of the gut flora could result in 
subsequent overgrowth of the endogenous micro flora or colonization with exogenous 
pathogens. The concept of translocation has been an hypothesized theory to explain 
the development of multiple organ failure appearing weeks after an initial insult.  
 
But rat and human small intestine behave differently when subjected to starvation or 
mucosal injury. Starvation in the rats can result in small bowel atrophy within 4 days 
[84], whereas the human bowel may remain nearly normal for nearly 2 weeks of 
starvation [85]. It is only with electronic microscopy, that a slight but significant 
decrease in the height of duodenal microvilli is observed. 
 
At their arrival in the intensive care, patients may experience a phase of shock (related 
to hypovolemia, response to illness) lasting 48 to 96h that is accompanied by a phase 
of intense catabolism. During this phase, surgical injury, trauma or critical illnesses 
result in hormone-mediated mobilization of endogenous substrate to protect 
homeostasis. There is a generalized increase in metabolic activity averaging 30-40% 
above resting metabolic rate equaling 900-1200 kcal/m2/day. So critically ill patients 
are hypermetabolic and have increased nutrient requirements. Endogenously increased 
metabolic activity is supported by release of stored energy. Under the mobilizing 
signal of the catecholamines, glucagon, insulin and corticosteroids, endogenous 
reserves are utilized in support of the metabolic response to injury [86, 87]. Although 
it is assumed that nutritional support is beneficial in this group of patients, there are 
no well-designed clinical trials to test this hypothesis. The rationale for nutritional 
support, therefore, is based upon clinical judgement. It is not known how long a 
critically ill patient can tolerate what is effectively starvation; the loss of lean tissue, 
which occurs in catabolic patients (20-40 g nitrogen/day), suggests that depletion to a 
critical level may occur after 14 days [88]. 
 
5.1: Glucose metabolism 
A prominent feature of the response to injury or sepsis is hyperglycemia. The initial 
increase in blood glucose after injury is due to the mobilization of liver glycogen. The 
hyperglycemia persists beyond the exhaustion of the glycogen supply. There is a 
marked increase in hepatic glucose production (due to hepatic gluconeogenesis) along 
with a reduction in glucose clearance. The hepatic gluconeogenesis use: amino acids 
(breakdown of muscles), lactate and pyruvate (coming from glycogenolysis and 
glycolysis of muscle), and glycerol (from the metabolism of triglycerides). A 
resistance to insulin is observed in peripheral tissues, such as skeletal muscle and 
attributed either to an inhibition of insulin secretion secondary to epinephrine 
(inhibition of insulin exocytosis) or to a post-receptor blockade. The increased 
gluconeogenesis and insulin-resistance result in poor utilization of both endogenous 
and exogenous carbohydrates in stressed patients. Moreover, glucose control with 
prevention of hyperglycemia is a dominant factor in improving mortality of critically 
ill patients. Increased insulin administration is associated with an increased risk of 
death [89, 90]. While there is still no proven mechanism to explain the detrimental 
effects of hyperglycemia, in vitro data demonstrate that the responsiveness of 
leukocytes stimulated with inflammatory mediators is inversely correlated with 
indices of in vivo glycemic control [91]. Other as-yet unproven explanations include 
exacerbation of polyneuropathy in critical illness or the risk of developing critical 
illness polyneuropathy, thereby prolonging mechanical ventilation, and undefined 
alterations in use of cellular energy substrates. Multivariate logistic regression 
analysis confirmed the independent role of blood glucose control in achieving most of 
the clinical benefits of intensive insulin therapy and underlines the importance of 
lowering the blood glucose level to strict normoglycemia [92]. 
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5.2: Fat metabolism 
After trauma, patients have increased lipolysis and utilize fat as their major fuel 
source: muscle lipoprotein lipase activity is increased and adipose tissue lipoprotein 
lipase is decreased. In case of sepsis, muscle lipoprotein lipase activity is decreased. 
Moreover, excessive or inappropriate inflammation and immunosuppression are 
components of the response to surgery, trauma, injury and infection in some 
individuals and these can lead, progressively to sepsis and septic shock.  
The hyperinflammation is characterized by the production of inflammatory mediators, 
while the immunosupression is characterized by impairment of antigen presentation 
and of T helper cell type-1 responses. Long chain n-3 fatty acids from fish oil 
decrease the production of inflammatory cytokines and eicosanoids. They act both 
directly (by replacing arachidonic acid metabolism) and indirectly (by altering the 
expression of inflammatory genes through effects on transcription factor activation). 
Thus, long-chain n-3 fatty acids are potentially anti-inflammatory agents and It is still 
matter of debate if this can be translated in patients with sepsis  [93].  By contrast, in 
acute respiratory distress syndrome, the debate concerning the use of long-chain fatty 
acids as opposed to physical mixture of medium- and long-chain fatty acids, 
specifically regarding their effect on gas exchange and pulmonary hemodynamics, 
still remains unresolved [94]. 
 
5.3: Protein metabolism 
Injury (surgical, traumatic and burn) and sepsis result in accelerated protein 
breakdown, manifested by an increase in urinary nitrogen loss, increased peripheral 
release of amino acids, and inhibited muscle amino acids uptake observed in sepsis. 
Labile protein reserves are mobilized in increased amounts. The amino acids are 
transported to the liver for conversion to glucose (gluconeogenesis) and biosynthesis 
of new protein necessary to ensure proper recovery. The negative nitrogen balance 
observed in such patients represents the net result of breakdown (increased) and 
synthesis (either increased or diminished). Erosion of protein stores (muscle, gut and 
skin) causes a decrease in the net weight and a muscle loss. This catabolic phase with 
erosion of protein stores results in a significant added morbidity and mortality [95, 
96].  
 
5.4: Nutritional support to critically ill patients 
Injured and septic patients do not respond to nutrients like normal or starved patients. 
The provision of protein to stressed patients is an important aspect of nutritional 
support. However, it is necessary to provide adequate non protein calories (lipid and 
carbohydrates), so that the administered and/or endogenous amino acids can be used 
as substrate for protein synthesis rather than as an energy substrate. This is 
particularly true because the catabolic state found in burns, trauma and septic patients 
markedly impairs the efficient utilization of exogenous nitrogen. However, even if 
adequate proteins are provided, it only partially attenuates the nitrogen losses [96].  
 
Compared to healthy volunteers, critically ill mechanically ventilated patients have 
delayed gastric emptying, usually associated with the use of opioids for analgesia, and 
with sedation [97]. But a manometric study done by Dive et al. [98], who compares 
healthy volunteers to mechanically ventilated critically ill patients, shows a loss of 
peristaltic activity in the stomach and, to a lesser degree, in the duodenum. Theses 
alterations in the electrical activity of the proximal gut cannot only be attributed to the 
use of opioids or dopamine or head injury. 
 
In case of head injury, Young et al. [99] showed that a profound traumatic response 
with increased energy expenditures, negative nitrogen balance, weight loss, 
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hypoalbuminemia and altered substrate oxidation is induced. Head injured patients are 
also known to have poor gastric tolerance to enteral feeding. The recommendations of 
nutritional support are to replace 140% of resting metabolism expenditure in non-
paralyzed patients and 100% of resting metabolism expenditure in paralyzed patients 
using enteral or parenteral formulas containing at least 15% of calories as protein by 
the seventh day after surgery. The preferable option is the enteral way [100].  
 
Nutritional support can be administered via enteral or parenteral way. Kudsk et al. 
[101] compared enteral nutrition to parenteral feeding in a prospective study on 
patients suffering from abdominal trauma. They found that enteral feeding is 
associated with significantly fewer cases of pneumonia, intra-abdominal abscess, line 
sepsis and infection. Only 18% of enteraly feed patients compared to 35% of 
parenteraly feed develop post-operative septic complications. The difference between 
groups is the greatest in the most severely injured patients. A meta-analysis on post-
operative septic complications conducted by Moore et al. [102] compares early 
enteral feeding to parenteral nutritional support and draws similar conclusions: early 
enteral nutrition in high-risk surgical post-operative patients is followed by a lower 
septic morbidity rate compared to total parenteral nutrition. 
 
6. Bacteremia and multiple organ dysfunctions 
 
Systemic blood infections with bacteria have multiple origins: oral or transmucosal 
passage of bacteria, catheter contamination, wound infections.... 
 
Oral microorganisms (more than 500 bacterial species have been encountered in the 
mouth) are known to cause systemic diseases in every human, but are usually 
eliminated by the host within minutes [103]. Transmucosal passage of bacteria 
through the intestinal mucosa is less frequent and could lead, in critically ill patients, 
to significant incidence if systemic sepsis occurs.  
 
6.1: Bacterial translocation 
Bacterial translocation is defined as the passage of viable bacteria or bacterial 
components from the gastrointestinal tract to extra-intestinal sites, such as the 
mesenteric lymph node complex, liver, spleen, kidney, and blood stream. Three basic 
pathophysiological conditions are necessary for bacterial translocation to occur in 
animal models [104]. These are:  
• Disruption of the ecological balance of the normal endogenous microflora, 
resulting in bacterial overgrowth with Gram positive enteric bacilli 
• Impaired host immune defenses 
• Physical loss or increased permeability of the intestinal mucosal barrier 
 
Diagram illustrating concomitant factors promoting bacterial translocation 
 
(See Fig #8) 
 
Adapted from [104] 
 
 
The presence of mucosal atrophy does not mean that intestinal permeability to 
bacteria or endotoxin, or both, will be increased and, conversely, the prevention of 
mucosal atrophy is not synonymous with the prevention of bacterial translocation 
[83].  
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Diagram illustrating the progressive atrophy of the villous height and crypt depth, 
bacterial proliferation and then translocation through the atrophied epithelial barrier 
 
(See Fig #9) 
 
       
These mechanisms can act in concert to promote synergistically the systemic spread 
of endogenous translocating bacteria to cause lethal sepsis. In animal models without 
physical damage of the intestinal barrier, bacteria translocate by an intracellular route 
through the epithelial cells lining the intestines and then travel via the lymph to the 
mesenteric lymph node complex. In animal models exhibiting damage to the mucosal 
epithelium, bacteria translocate intercellularly between the epithelial cells to directly 
access the blood [105]. Histological mechanical damage to the gut mucosal barrier 
and spread of bacteria from the gut is observed in an animal model of protein 
malnutrition associated to endotoxemia. The mortality rate is directly related to the 
degree of malnutrition and histological damage is associated with higher lethal effects 
of endotoxin [83, 106].  
 
These same conditions are commonly seen in the critically ill or injured patient at risk 
of developing enteric bacteremia or multiple organ failure. As starvation and protein 
malnutrition have been reported to: impair host immune and antibacterial defenses, 
disrupt the normal ecology of the gut microflora and lead to mucosal atrophy, there 
are many reasons to believe that nutritional variables are important modulators of gut 
barrier function and bacterial translocation.  
 
6.2 Multiple organ dysfunctions 
Multiple organ failure (MOF) is a state often observed in the ICU, which etiology is 
not clearly established. It usually follows an infection, but the causal relationship 
between infection and MOF is not proved even if it is frequently observed [107]. 
Prevention of MOF is now recognized and include aggressive resuscitation of 
hemodynamically unstable patients, careful assessments to avoid missing clinically 
significant injuries, early operative treatment of all possible injuries, early nutritional 
support and early diagnosis and prompt treatment of infectious complications [108]. 
The treatment of underlying disease remains the cornerstone of the care of critically ill 
patient to prevent MOF. 
 
The multiple organ failure and its consequences and treatment, which are not of a 
primary importance for this study, will not be developed further.  
 
7.  Importance of the route of nutrition 
 
The route by which patients are fed may influence the immuno-inflammatory and 
metabolic response to injury, thus affecting the incidence of infectious complications 
and modulating clinical outcome. The works of Moore et al. [102] and Kudsk et al. 
[101] demonstrate an association between total parenteral nutrition (TPN) and a 
higher incidence of septic complications when compared with total enteral nutrition 
(TEN). Hadfield et al., [109], studied the effect of enteral nutrition (EN) and 
parenteral nutrition (PN) on gut mucosal permeability in human critically ill patients. 
They found that compared to a control group, gastrointestinal tract dysfunction 
(reduced absorption and increased permeability) are evident in critically ill patients. 
The introduction of an EN is followed by a significant decrease in gastrointestinal 
(GI) permeability, whereas the use of TPN results in the perpetuation of the loss of 
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mucosal integrity. A significant difference between both methods of nutrition is seen 
after 9 days of stay in the ICU. 
 
7.1 Parenteral nutrition 
With intravenous TPN, nutrients do not directly reach the liver; they have to pass 
through the lung and the systemic capillaries before they reach the hepatocytes. That 
is probably why the parenteral way of nutrition, although it is relatively practical to 
manage, is associated with numerous complications. A non-exhaustive list of the latter 
includes: 
• Dysfunctions of the gut (alteration of the gut mucosa, bacterial translocation) 
• Immune effects (impaired immune function, immunosuppressive effect) 
• Catheter related problems (infections, thrombosis, arterial puncture, 
pneumothorax) 
• Metabolic effects (secondary bone disease, hepatic and renal dysfunction, 
hyperglycemia, hyperinsulinemia, elevated lipogenesis, biological acute 
pancreatitis) 
 
Relevant complications for this study are developed below. 
 
7.1.1: Morphologic changes in the intestinal mucosa related to parenteral nutrition 
It is the presence or absence of nutrients in the intestinal lumen, which affects gut 
structure and function. If adequate nutrients are provided by intravenous route, 
bypassing the intestine, the intestine still atrophies (review of animal and human 
studies [110], human case-report [111, 112]). Intestinal adaptation (increasing 
intestinal length and weight) occurs rapidly if EN is added to PN. Intestinal 
morphologic and functional changes in humans are substantially less significant than 
observed in animal models. But the loss of mucosal structure may be sufficient in 
these patients to cause increased intestinal permeability (intracellular edema develop 
during TPN and resolve with enteral refeeding) [113]. TPN in itself does not influence 
the overall mortality rate of surgical or critically ill patients when compared to an oral 
diet associated with the administration of intravenous dextrose. However, when the 
studies including only critically ill patients are analyzed, Heyland et al. demonstrate a 
significant increase in complication and mortality rates in comparison to the studies of 
surgical patients [114].  
 
7.1.2: Bacterial translocation related to TPN 
Several studies on animals have investigated the fact that TPN is associated with 
bacterial translocation and increase in morbidity and mortality.  
 
The initial study evaluating the route of nutrient administration on bacterial 
translocation was by Alverdy et al. (administration of a TPN to rats [115]). They 
hypothesized that bacterial translocation results from different factors including: 
hypotension, blood loss, impaired host immune defenses and disruption of the 
ecological balance of the normal microflora of the gut (happens in case of parenteral 
feeding [116]).  
Other studies on animal models show that: 
• TPN or a single amino acid –based formula administered IV increase 
mortality in animals after hemorrhage (secondary hypotension with 
subsequent reduced intestinal blood flow) but on the other hand, the 
administration of EN is associated with zero mortality and a protection of 
liver functions under the same conditions [117]. Bacteria, and/or toxin, induce 
release of cytokines (i.e. tumor necrosis factor, interleukins) from hepatic 
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macrophages and complement activation, which is thought to initiate 
progressive multiple organ failure and death after hemorrhage.  
• The induced bacterial translocation, following the administration of the same 
TPN solution via oral and intravenous route, can be reversed by dietary fiber 
[83]. The protective effects of cellulose fiber seemed to be related to its ability 
to stimulate trophic gut hormones. Even a small amount of oral nutrition in 
combination with a parenteral nutrition prevents increases in the intestinal 
permeability and bacterial translocation associated with TPN [113, 118].  
 
Another hypothesis could be that bacterial translocation is the consequence rather than 
the prime cause of systemic sepsis. Although the strict TPN is associated with gut 
mucosal atrophy and increased permeability to lactulose, the incidence of bacterial 
translocation is not significantly different between groups (TPN intra venous; TPN via 
enteral way; TPN solution administered half enteral, half parenteral; normal EN) in 
the study of Illig et al. on a rat model [119]. A septic state, occurring in association 
with TPN or trauma and apparently originating from the gut, may be initiated by 
macromolecules (cytokines, other inflammatory mediators) arising from the gut itself 
rather than from bacteria within the lumen.  
 
7.1.3: Modifications of the GALT (Gut Associated Lymphoid Tissue) related to TPN 
Alverdy et al., who studied the effect of TPN on the gastrointestinal immunity of rats, 
found that in parenteral nutrition groups, a diminution of the S-IgA is observed which 
returns to normal levels after resumption of enteral feeding [12]. Wu et al. [11] made 
the hypothesis that GALT is modified in case of TPN to explain the increased 
susceptibility to pneumonia and other complications associated with this nutritional 
support in critically ill and critically injured patients, compared with enteral feeding. 
They demonstrated in their first work that intra venous TPN significantly reduces 
GALT mass by depleting Peyer’s patches, lamina propria and the intraepithelial space 
of T and/or B cells and decreasing the CD4+/CD8+ ratio within the lamina propria 
[120]. Reduction in GALT cell population occurred simultaneously with drops in both 
intestinal and respiratory IgA levels.  
 
7.1.4: Septic complications 
Catheter sepsis rates related to TPN are variable and depend on several patient-
specific factors. These factors include the presence of immunosuppression or critical 
illness, the use of multiple intravascular catheters, bacterial translocation and the 
insertion at femoral vein site [121, 122]. If the duration of catheterisation increase 
[122] or not [123] the rate of catheter related sepsis remains controversial. 
Nevertheless, a prevention strategy targeted on the insertion and maintenance of 
vascular access [124], use of ionic silver (anticoagulant/antimicrobial flush solution) 
and antimicrobial impregnation of catheter and dressings [125] in order to decrease 
catheter-related sepsis, are the only way to diminish the incidence of such acquired 
infections  
 
7.1.5: Metabolic complications 
The frequency rate of hyperglycemia and other complications are not related to the 
quantity of intra venous delivery of glucose. Indeed, McCowen et al. found in patients 
receiving 5 days of normal (standard weight-based regimen) versus hypocaloric (1 L 
containing 70 g protein and 1000 kcal) TPN, that the average level of glycemia was 
similar. The control group (normocaloric) showed a trend toward a higher insulin 
requirement than hypocaloric group. Furthermore, the numbers and types of infections 
were also similar [126]. 
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The most frequent hepatobiliary complications associated with TPN include hepatic 
steatosis, intrahepatic cholestasis and biliary sludge. Cholestasis predominates in 
infants, steatosis in adults, and biliary sludge in both. Other less frequent 
complications are steato-hepatitis and gallstones. All hepatobiliary complications are 
more likely to occur after extended periods of TPN, and are prevented by the 
concomitant consumption of nutrients by the enteral route. The pathogenic causes are 
multiple and only partially known. They include lack of gastrointestinal stimuli for 
biliary secretion and gall-bladder motility, abnormalities in bile acid metabolism, the 
presence of sepsis, and the potentially unfavourable effects of individual components 
in the TPN formulae, including an excess of calories [127].  
 
TPN has also been reported to increase sympathetic nervous activity [128].  
 
7.1.6 Immunosuppressive effects of intravenous fat 
Immunosuppressive effects of intravenous fat are well known. Intravenous long-chain 
triglycerides reduce the functions of the reticulo-endothelial system [129], neutrophils 
[130] and the ratio of T helper to T suppressor cells [131]. This is illustrated by the 
fact that TPN-fed animals and human patients undergoing skin grafting or solid organ 
transplantation have better graft survival [132]. 
 
 
7.2 : Enteral nutrition (EN) 
The enteral way of nutrition is more physiological, as it preserves the hepato-
splanchnic axis, and seems to be superior to parenteral nutrition by reducing 
infectious morbidity and maintaining gastrointestinal immunological function [101, 
102, 133].  
 
There are several advantages associated with EN: 
• Maintenance of mucosal gut and blood flow 
• Avoidance of translocation with maintenance of the barrier function 
• Maintenance of the enteral bacterial flora [106] 
• Prevention of stress ulceration  
• Maintenance of the immune function of the gut with the persistence of 
secretion of the S-IgA  
• Lower cost 
The enteral nutritional support seems to be more efficient than the parenteral route, if 
administered very early. But it has to be maintained during at least four days to have a 
sufficient caloric and nutritional support that is similar to the nutritional support 
provided via the parenteral route, without associated complications. Nevertheless, 
several technical problems including the lack of reliable access and their related 
complications limit the use of this technique. Contraindications to its administration 
are: ileus, eso-gastric surgery, gastro-intestinal bleeding, pancreatitis and 
inflammatory bowel disease. 
 
7.2.1: Complications related to enteral nutrition 
Relevant complications are regurgitation or vomiting of the gastric content, gastro-
esophageal reflux, gastrointestinal intolerance (high gastric residue, diarrhea, 
constipation), abdominal distension and aspiration pneumonia [134]. Clinical and 
biological surveillance techniques can generally prevent these complications, and 
actually only sterile, commercially prepared solutions are administered. In addition, 
Heyland et al. [135] showed that there are also other barriers in the application of 
enteral nutrition research to daily clinical practice, because of physician practice 
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patterns. Management protocols, that include every situations or complications, are 
necessary for the application of enteral nutrition, and to avoid early withdrawal. 
 
Gastrointestinal complications 
In the multicenter cohort study of Montejo et al. [134], more than 60% patients 
present gastrointestinal complications during their feeding course, high gastric residue 
(define as more than 200ml) being the more frequent and appearing earlier. The naso-
gastric tube is also associated with oesophagitis attributed to gastro-esophageal reflux, 
which can be observed within 24 to 36 hours and more commonly after a week or 
more of naso-gastric intubation [136]. The frequency of diarrhea is highly variable, 
from 14,7% [134] up to 50% [137], but definition and reporting varies considerably 
between studies. 
 
Pulmonary complications  
Aspiration pneumonia is the most frequent encountered complication. The reported 
incidence of nosocomial pneumonia in the ICU, related to mechanical ventilation, 
varies between 10 to 65% [138-140]. If associated with EN, the incidence is of 2,4 per 
1000 tube-feeding days [141]. This incidence correlates directly with the rate of 
gastric colonization by Gram-negative bacilli [138]. It is estimated that at least 50% of 
the pneumonia case are due to gastro-esophageal reflux, while the remaining cases are 
caused by oro-pharyngeal aspirations and/or are of atelectatic origin [1]. Hypothesis 
to explain secondary colonization of the lung is that bacteria coming from the stomach 
colonize the naso-gastric feeding tube and then the oro-tracheal tube (89% of 
patients), in patients that are mechanically ventilated and that cannot expectorate; 
some microorganisms also come from the oropharynx [139, 140].  
 
The restoration of an acid gastric pH, which prevents gastric colonization, associated 
with normal gastro-duodenal motility might help prevent pneumonia in mechanically 
ventilated patients. Lee et al. [142] confirmed this theory with an intermittent feeding 
protocol (reduced gastric pH during fasting time). They observed a lower incidence of 
pneumonia in the intermittent feeding group (12%, 3/26) compared to a group of 
continuously feed patients (54%, 13/24) observed in a previous study [139]. They also 
found a correlation between high morning gastric pH (> 3.5, persistently) and the 
occurrence of pneumonia. This is in agreement with other studies, suggesting that 
reduced gastric acid production or artificial elevation of the gastric pH (via antacid or 
cimetidine) is a contributory factor in gastric bacterial overgrowth and subsequent 
pulmonary colonization and that acidified enteral feeds are effective in reducing 
gastric colonization [133, 143]. A trend to a lower incidence of pneumonia and lower 
mortality rate is observed in patients whose gastric pH is not altered [144]. Stress 
ulcer prophylaxis can be done either with sucralfate (antibacterial properties, no 
clinically relevant gastric pH modifications) which seems better than ranitidine in 
reducing the risk of late onset pneumonia [145] or with ranitidine which seems better 
than sucralfate for the prevention of upper gastrointestinal bleeding [146].  
 
Impaired gastric and small intestine motility promotes bacterial overgrowth in the 
duodenum. In case of duodenal reflux, gastric colonization and subsequent retrograde 
bacterial colonization of the lower respiratory tract can occur in mechanically 
ventilated patients [147]. 
 
Pulmonary aspiration of gastric content is partially prevented by a semi-recumbent 
position (45° angle) and elevating the head [148, 149], but is favored by a naso-gastric 
tube (double the likelihood of gastro-esophageal reflux [150]) and an oro-tracheal 
intubation, as mentioned at the beginning of chapter #4. Positive gastric pressure 
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during ventilation may increase the esophageal reflux of gastric content [149]. The 
cuff of the tracheal tube may also compromise function of the upper esophageal 
sphincter, increasing micro aspiration into the lower respiratory tract [148, 149].  
 
7.2.2: Surveillance techniques 
The surveillance techniques include a close monitoring of the position of the gastric 
tube and its functionality, a monitoring of the gastrointestinal emptying with 
measurement of the gastric residual volumes several times a day. The abdominal 
distension and the emission of stools are to be evaluated every day. Blood glucose, 
transaminases and albumin are checked from time to time and white cell count is 
monitored if an infection is suspected [150, 151]. Radiography can be done to ensure 
the position of the gastric tube, and need to be done if aspiration pneumonia is 
suspected. 
 
7.2.3: Difficulty with the delivery 
High gastric residual volume is a frequent cause for cessation of enteral nutrition. The 
question is how to judge if the residual volume observed corresponds to tolerance or 
not to the enteral feeding. Number of values has been advocated as the designated 
level indicating tolerance or intolerance, ranging from 75 to 150mL of gastric aspirate 
[33]. McClave et al. [152] made a blind comparison between measure of gastric 
residual volume, physical examination and radiographic findings to establish the 
validity, range and limitation of this parameter. First, they found that in critically ill 
patients, a residual volume of up to 400ml does not necessarily indicate intolerance, 
but nevertheless residual volume should be checked regularly after initiation of enteral 
feeding. According to their protocol, if the residual volume is over 200ml in patients 
with naso-gastric tube, or over 100mL in those with gastrostomy tubes, the patient 
should be observed closely but feeding need not to be stopped. Low residual volume 
does not seem to guarantee tolerance and adequate gut motility, because abnormality 
still appeared on physical examination and radiography. They found that there is no 
difference in residual volume obtained from the supine or the right lateral decubitus 
position. They make several recommendations:  
• Residual volumes are more easily obtained with a large 60mL syringe 
• Residual volumes should be checked frequently at the initiation of enteral feeding 
(every two hours), and less frequently if good tolerance is observed 
• Content of the aspiration should be returned to the patient 
• Residual volume does not need to be checked if the tube is positioned below the 
pylorus 
Jejunal tube feeding seems to be superior to gastric feeding in the study of 
Montecalvo et al. [153] with a higher caloric intake (target intake of 61 versus 47%) 
and a lower rate of pneumonia (with only two case are observed in the gastric group). 
But other studies in non-ventilated patients [154] or head injured patients [155] show 
that transpyloric passage of feeding tube is followed by a same complication rate as 
gastric feeding. Moreover, the position of the jejunal tube is difficult to achieve 
(frequent use of an endoscopic placement), and the tube moves frequently back into 
the stomach. 
 
7.2.4: Time to initiation of enteral feeding and rate 
EN should be preferred where possible and be started as early as possible, to stimulate 
gut immunological function and maintain gut mucosa as soon as possible.  
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In animal studies, early enteral feeding has shown benefits. Zaloga et al. [156], 
compared rats receiving no EN or delayed EN (>72h), with rats receiving early 
feedings (within 24 hours of injury). They found that early EN promotes greater 
wound strength after abdominal surgery. After burn injury, early EN can prevent 
hypermetabolism via preservation of gut mucosal integrity [157] and diminish 
catabolic phase [158], lower the rate of translocation [159] and prevent increased 
secretion of catabolic hormones [157].  
 
In human patients with major abdominal trauma and burn patients, those patients 
receiving early EN within 12 to 18hrs of injury have a lower infection rate than 
control patients [160, 161]. Immediate EN compared to gradual reintroduction of EN 
after bowel resection is also feasible and results in improved wound healing response 
and less bowel obstruction [162]. The results of a meta-analysis comparing early EN 
to TPN done by Moore et al. [102], on postoperative septic complications, show that 
early EN is feasible even in high-risk surgical patients. Septic morbidity rates 
observed in case of EN are lower than in case of TPN, as mentioned at the end of 
chapter #5 and as illustrated below. 
 
Postoperative septic complications (Phase II) 
 
(See Fig #10) 
 
Adapted from [102] 
 
But initiation of enteral feeding, achieving tolerance and nutritional requirement goals 
is difficult. Heyland et al. [163] evaluated a protocol of administration of early enteral 
feeding on critically ill mechanically ventilated patient. EN started within 24 hours of 
admission (16,4 ± 7,9 hours) and tolerance was assessed. Intragastric feeding was 
initiated at 10mL/hr rate and gastric residues were checked every 4 hours. Every 12 
hours, the rate was increased by 25mL/hr if the gastric residual volume was less than 
200mL. If the residual volume was over 200mL and accompanied by feeding 
intolerance signs, feeds were discontinued for 4 hours then reassessed every 4 hours. 
Initiation of EN took time (62% of patients received less than 100mL of feed the first 
day; by day two, 94% of patients had received some gastric feed). The average time 
from admission to ICU to tolerance of EN was 3,8 ± 1,6 days, 42% of patients 
achieved tolerance at that time. In their study, high gastric residue was the limiting 
fact to the success of early feeding.  
 
In order to diminish gastric residue and achieve better tolerance to early enteral 
feeding, prokinetic drugs can be used.  
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AIM OF THE STUDY 
 
Critically ill patients suffer from protein and caloric loss during their stay in the 
intensive care unit (ICU). It is now admitted that they are in a catabolic state at their 
arrival in the ICU and that they need a nutritional support. The intuitive concept of an 
early nutritional support to maintain host defense and preserve organ function has 
been well studied for many years and is admitted, but scientific evidence are still 
missing. The enteral route should be preferred if possible (maintenance of gut 
mucosal, avoidance of complications associated with TPN). As mentioned in the 
introduction, critically ill patients generally have delayed gastric emptying for 
multiple reasons (mechanical ventilation; circulatory failure; medications including 
opiates and dopamine; post-surgical ileus, neurological trauma and underlying disease 
such as diabetes mellitus).  
 
We designed a study to investigate the effect of adding cisapride to an early enteral 
feeding protocol, and how it would improve the tolerance to enteral nutrition in 
sedated critically ill mechanically ventilated patients. The design was a prospective 
double blind randomized controlled trial. The main endpoint of the study was to 
estimate the tolerance to early enteral feeding measured by gastric aspirate and daily 
quantity of enteral support 
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MATERIAL AND METHOD 
 
Patients protocol was submitted and approved by the ethical committee of Geneva 
University Hospital in January 1997 and by the ethical committee of the Hôpital des 
Cadolles, Neuchâtel, by mutual recognition of local commissions and by Dr Damke, 
at the OICM (Office Intercantonal des Médicaments). The drugs: cisapride and the 
identical matched placebo were donated by Janssen-Cilag, which provided them in 
randomly numbered bottles. The randomization key was maintained undisclosed by 
the pharmacy of the Hôpital des Cadolles. A physician involved in the study obtained 
written consent from each patient or his nearest family member.  
 
Inclusion criteria: 
 
From Mai 1997 until March 1999, patients were recruited in the ICU of the Hôpital 
des Cadolles, Neuchâtel, Switzerland and in the surgical ICU of the Geneva 
University Hospital, Geneva, Switzerland. All patients admitted in the above 
mentioned units and meeting the following criteria were included in the study: 
• Mechanical ventilation lasting for less than 24 hours 
• Expected length of enteral feeding of five or more days 
 
 
Exclusion criteria: 
 
• History of recent upper digestive surgery (oesophagus, stomach, duodenum) 
• Upper gastrointestinal bleeding 
• Intestinal inflammatory bowel disease 
• Liver failure, or cirrhosis confirmed by biopsy 
• Recent abdominal trauma 
• All conditions known to be a contra-indication to enteral feeding (mechanical 
ileus, paralytic ileus) 
• Concomitant administration of the following drugs (mainly drug metabolized via 
cytochrome P450 3A4):  
o Azolated antimycotics drugs such as fluconazole, itraconazole, ketoconazole 
and miconazole  
o Macrolides antibiotics such as erythromycin and clarithromycin 
o Protease inhibitors such as ritonavir, indinavir 
o Nefazodone 
o Drugs known to promote long QT syndrome such as class Ia anti-arrhythmic 
and class III anti-arrhythmic 
o Tricyclic and tetracyclic antidepressant drugs 
o Some anti psychotics and anti histaminics whose contra-indications appeared 
in the drug information  
• Concomitant administration of parenteral nutrition 
• Inclusion of previously screened and excluded patients (after re-intubation for 
example) was not allowed 
 
Design of the study 
 
The time of initiation of the enteral nutritional support was planned to be during the 
first 24 hours following the beginning of the mechanical ventilation. Enteral nutrition 
(EN) was administered through a naso-gastric tube (Salem 14Fr or 16Fr). The correct 
position of the tube in the stomach was assessed initially by chest x-ray and 
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subsequently by air inflation through a 60mL-syringe and auscultation of a gastric 
sound. The correct position of the naso-gastric tube was assessed twice a day.  
EN composition were:  
 
 Type of formula Protein content 
(g/100ml) 
Calories 
(kcal/100ml) 
Neuchatel Fresubin ® normal 3.8 100 
 Fresubin ® plus 3.8 100 
 Fresubin ® MCT 7.5 150 
Geneva Osmolite fibre ® 4.2 100 
 Novasource energie ® 5.6 150 
 
 
The protocol consisted in the blinded administration of either cisapride or its matched 
placebo via the naso-gastric tube four times daily in patients receiving enteral 
nutrition 22h/24h. The protocol was established on a 24-hours scale for each patient. 
Nutrition was continuously administered during 11 hours followed by 1 hour fast. 
Gastric aspirate was then measured. Depending on the result of the gastric residue, EN 
was continued or stopped. After 24 hours tolerance to the rate of administration of 
nutrition, the administration rate was increased following the protocol. Cisapride or its 
matched placebo was administered after the measurement of the gastric residue and 6 
hours later. 
 
 
Feeding protocol on 24 hours 
 
 Hours: 
  
 
 
 
Time: 
  T0  T1    T2  T3  T4          T5  T6
 0   6    11   12  18          23 24
 
 
 
 
 
 
 
 
 
 
 
T0 to T6  24 hours interval 
 T0 to T2:   eleven hours of continuous enteral feeding 
 T0:  administration of 10 ml of cisapride or his placebo 
(cisapride/placebo)  
 T1:   administration of 10 ml of cisapride/placebo 
 T2 to T3:   1 hour fast 
 T3:   measurement of the gastric residue and administration of 10 ml 
of cisapride/placebo 
 T3 to T5:  eleven hours of continuous enteral feeding 
 T4:   administration of 10 ml of cisapride/placebo 
 T5 to T6:   1 hour fast 
 T6:   measurement of the gastric residue and administration of 10 ml 
of cisapride/placebo 
 - 38 - 
Based on data reported in the literature [152] and clinical experience as explained in 
the discussion part, we defined a gastric aspirate equal to or lower than 250mL as 
normal and the patient was qualified as tolerant to enteral nutrition. The procedure to 
be followed in case of normal or larger gastric aspirate was described in the protocol 
and explained to the nurse in charge of the patient.  
 
Description of the procedure to follow in case of normal or larger gastric aspirate: 
 
• Normal gastric aspirate (≤ to 250mL): 
 
The rate of enteral feeding is progressively increased, from 500mL (250mL/11 h) on 
day #1, to 1000mL (500mL/11h) on day #2 and 1500mL (750mL/11h) on day #3. 
The rate of enteral feeding is then adjusted to give 25 to 30 kcal/kg/day per patient.  
 
• Larger gastric aspirate (>250mL): 
  
The entire gastric aspirate is reintroduced in the stomach and the enteral nutrition 
discontinued during 4 hours. 
Following 4 hours of fasting, gastric aspiration is repeated: 
• If the aspiration is ≤ 250mL, it is given back to the patient and enteral nutrition is 
reintroduced at the same rate as before being discontinued. 
• If the aspiration is > 250mL, the total gastric aspirate is given back to the patient, 
and 10 ml of cisapride/placebo is given 2 hours later. Fast is maintained during 4 
additional hours. The gastric aspirate is then measured again: 
o At this time, if the aspiration is ≤ 250mL, it is given back to the patient and 
enteral nutrition is reintroduced at a rate at which tolerance has already been 
observed; if tolerance was not previously observed, enteral feeding is 
reintroduced at a rate of 250mL/11 hours. 
o If the aspiration is > 250mL, only 250mL are given back to the patient, and 
fast is maintained during 4 additional hours. The gastric aspirate is then 
measured again: 
 At this time, if the aspiration is ≤ 250mL, it is given back to the patient 
and enteral nutrition is reintroduced at a rate at which tolerance has 
already been observed; if tolerance was not previously observed, enteral 
feeding is reintroduced at a rate of 250mL/11 hours. 
 If the aspiration is > 250mL, the study is stopped and a total parenteral 
nutrition is introduced. Gastric aspirate are still measured at the same 
time points. 
 
(See Fig #11 for an algorithm) 
 
 
In case of intolerance to the rate of enteral nutrition (defined as a gastric aspirate 
greater than 250mL), the cisapride/placebo solution was still administered at the 
planned time. If enteral nutrition is restarted with a new time scale, the time of 
administrations of the cisapride/placebo solution are adapted. 
 
Patient fulfilling one of the following predefined criteria were considered as intolerant 
to EN: 
• More than three consecutive gastric aspirates > 250mL following the protocol 
explained above. 
• Vomiting more than once a day 
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If patient in either group met criteria for intolerance to enteral nutrition, a trial was 
attempted with the administration of 10 mg of cisapride in an open label fashion, 
while maintaining the same time scale as planned for cisapride/placebo. If this test 
was inconclusive, the patient was considered intolerant to enteral nutrition.  
 
Clinically significant nosocomial respiratory infection was defined when criteria 
originally developed by Johanson et al [164] and adapted by Cook et al [165] were 
met (chest X-ray, clinical and chemical changes):  
• Definite infection: radiographic appearance or progression of pulmonary 
infiltrate; fever; leucocytosis; and purulent tracheal secretions. 
• Probable respiratory infection: fever; leukocytosis; and either a new or a 
progressive radiographic infiltrate, or the presence of purulent secretions. 
Investigations were done as previously reported by Pingelton et al [140]. 
 
The study was terminated when the patient discontinued enteral nutrition support, 
initiated concurrent oral nutrition, or was discharged from the ICU. 
 
 
Clinical collected data  
 
1. Patients’ demographics characteristics:  
• Age, Gender, 
• Admission date in the ICU, date of randomisation, number of hours between 
tracheal intubation and beginning of EN. Duration of tracheal intubation, 
enteral and/or parenteral nutrition, ICU and hospital length of stay and ICU 
and hospital outcome. 
• Severity scores at the ICU admission: SAPS II (Simplified Acute Physiology 
Score [166]), multiple organ failure: SOFA (Sequential Organ Failure 
Assessment [167]) 
• Primary admission diagnosis and co-morbidities 
2. Repeated data collected longitudinally 
• Severity scores: SAPS II, SOFA  
• Concomitant medications 
• Laboratory tests:  
• Urea, amylase, lipase, ASAT, ALAT, albumin, potassium, and 
calcium: on day #1 and #6 
• Arterial blood gazes, platelets, bilirubin, and creatinine, daily 
• Nitrogen balance: on day #3. UUN is the urinary urea nitrogen excretion (in 
grams) in 24 hours, total protein intake (in grams) in the same 24 hours 
[168]: 
   nitrogen balance (g)=(protein intake (g)/6.25) – (UUN+4)  
• Caloric and protein intake was calculated daily 
• Gastric aspirate every 12 hours 
• Presence of nausea, vomiting or diarrhoea were recorded 
• Gastroscopy between day #3 and #5 to confirm the absence of gastric residue 
after gastric aspiration through the naso-gastric tube and validate the results 
of gastric aspiration. (See Fig #12 for the procedure) 
• Chest X-ray to confirm the correct position of the oro-tracheal tube and the 
naso-gastric tube on day #1 and repeated as necessary (in case of suspicion of 
aspiration pneumonia) 
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3. Nutritional support 
• Time and reason for cessation of EN 
• Duration of enteral support 
• Time to reach target nutrition rate 
• Time and reason for initiation of parenteral nutrition (PN) 
 
The main results are:  
• Daily caloric intake 
• Tolerance to EN (gastric residue every 12 hours, nausea, vomiting or diarrhoea) 
•  Length of ICU and hospital stay as well as ICU and hospital vital status 
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STATISTICAL ANALYSIS 
 
Power calculation: In order to reach a 50% difference in the gastric residue between 
both groups with a two-sided alpha level of 0.05 and a power of .8, 20 patients were 
required in each arm, for a total sample size of 40 patients. After the enrolment of 32 
patients in the study protocol, an interim analysis was performed. Since significance 
was reached at this point, the study was stopped early. 
 
Confirmatory data analysis: We evaluated the distribution of baseline characteristics 
using t-test or frequency tables, as appropriate. For variables that were measured 
repeatedly, summary measures were calculated by averaging over all time points, so 
that each individual only contributed one observation. A two-tailed t-test was used to 
compare mean values of gastric residue, caloric and protein intake between patients 
assigned to the cisapride and the placebo groups. Because of the longitudinal nature of 
the data and the large inter-individual variability, we used generalized linear mixed 
models with random effects to analyze the effect on treatment on the amount of 
gastric residue, on the daily caloric intake, as well as on the daily protein intake.   
 
The generalized linear mixed model for normal data is a linear repeated measure 
analysis. Our model is a repeated measure analysis. Fitting this model is equivalent to 
the model requested by reviewer. In addition, this model is more flexible in that it 
better handles missing data, i.e. subjects without complete data are not excluded from 
the analysis, whereas the traditional repeated measure ANOVA excludes subjects 
without complete data. 
 
All values are expressed as mean ± standard deviation (SD). A p<0.05 was considered 
statistically significant. The STATA statistical software, version 7.0 (Stata 
Corporation, TX) was used for all analyses. 
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RESULTS 
 
1. Demographic data 
 
Thirty-two patients pooled together (28 admitted to Neuchâtel Hospital and 4 to 
Geneva University Hospital) were screened and randomized to receive either 
cisapride (n=16) or placebo (n=16). The patient characteristics are shown in Table #1.  
 
Table #1 :  Patients’ demographic characteristics 
 
Parameter Cisapride group Placebo group 
Number of patients 16 16 
Age, yrs, mean ± SD 64 ± 14 67 ± 10 
Gender (male/female) 11/5 10/6 
SAPS II score at ICU admission, mean ± SD 37.8 ± 12.2 37.9 ± 12.6 
Total SOFA score at ICU admission, mean ± SD 8.5 ± 4.0 7.4 ± 2.0 
Primary diagnosis (n°)   
Cardiogenic shock 2 2 
Cardio respiratory arrest 1 3 
Liver disease/GIT illness 0 2 
Multiple trauma 3 0 
Neurological disease 1 2 
Pneumonia/acute respiratory failure 5 7 
Septic shock/multiple organ failure 4 0 
ICU mortality rate (%) 7 (43%) 7 (43%) 
Duration of ICU stay, days, mean ± SD 9.9 ± 5.2 11.6 ± 7.0 
Time from ICU admission to start of EN (hours, mean ± 
SD) 
13.0 ± 14.6 13.4 ± 6.4 
Duration of enteral nutrition support, days, mean ± SD 5.6 ± 3.1 5.4 ± 2.2 
Duration of oro-tracheal intubation, days, mean ± SD 6.2 ± 4.0 6.8 ± 4.9 
 
SAPS II: Simplified Acute Physiology Score [166] 
SOFA: Sequential Organ Failure Assessment [167] 
ICU: Intensive Care Unit 
GIT: Gastro-Intestinal Tract 
EN: enteral nutrition 
 
2. Trial profile and tolerance to enteral nutrition 
 
The trial profile is summarized in Table #2. Six patients (three in each randomization 
groups) were declared intolerant to enteral feeding and received parenteral nutrition. 
The clinical course of the patients that did not tolerate enteral feeding is detailed 
below (d: known diabetic patient) 
 
Cisapride group (c patients thereafter):  
• Patient #2, #3d and #27 were declared intolerant to enteral nutrition (EN) after 
48h due to high volume gastric aspirates at repeated intervals. In patient #2 the 
gastric residues did not return to normal for a long period of time after 
discontinuation of EN but cisapride was never given in an open labeled 
fashion. In patients #3 cisapride was given in an open labeled fashion on day # 
3 and gastric residue normalized on day #5. Finally, concerning patient #27, 
the gastric residue normalized on day #3 and cisapride was never given in an 
open labeled fashion. 
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Placebo group (p patients thereafter): 
• Patient #21d, #22d and #24 were declared intolerant to EN after 48h due to 
high volume gastric aspirates at repeated intervals. In patients #21 cisapride 
was given unsuccessfully in an open labeled fashion on day #3. Indeed, gastric 
residue normalized only temporarily on day #4. In patients #22, the treating 
physician tapered down the rate of EN and concomitantly started TPN. EN 
was discontinued on day #3 for persistent high gastric residue. Finally, for 
patient #24, the gastric residue normalized on day #4 and cisapride was never 
given in an open labeled fashion. 
 
3.Effect of cisapride administration on daily gastric aspirates  
 
The mean and median daily gastric (Graphic #1 and Graphic #2-see APPENDIX I) 
aspirates were 71mL ±23mL and 76mL (min-max range: 33-99mL) respectively in 
the cisapride group and were 132mL ±36mL and 136mL (min-max range: 70mL-
181mL) respectively in the placebo group (p<0.005). The output of the statistical 
analysis is displayed in APPENDIX II. 
 
Graphic  #1  Mean daily gastric aspirate at baseline, and for the following 6 
days in patients randomized to receive enteral cisapride (n=16) or 
enteral placebo (n=16) 
 
 
G
as
tri
c 
as
pi
ra
te
 (m
l)
Days
 Cisapride  Placebo
1 2 3 4 5 6
50
100
150
200
 
 
 
4. Effect of cisapride administration on daily enteral nutrition, caloric and protein 
intakes 
 
Since gastric aspirates were always reinjected in the nasogastric tube except if 
superior to 250 ml, oral intake takes into account the amount prescribed plus the 
gastric residues reinjected. 
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Data for protein and caloric intake are derived from total oral intake and type of 
enteral nutrition used for the patients. 
 
The three following graphics shows the overall mean on the six days of the study 
protocol of the daily enteral intake in each randomization group, with the amount of 
EN, protein and caloric intake:  
 
Graphic #3 Box and whiskers display of the mean and interquartile range of 
total daily EN intake (=mean oral intake), in patients randomzied 
to received cisapride (n=16) or placebo (n=16) 
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Graphic #4  Box and whiskers display of the mean and interquartile range of  
daily protein intake, in patients randomized to received cisapride 
(n=16) or placebo (n=16) 
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Graphic #5  Box and whiskers display of the mean and interquartile range of  
daily caloric intake, in patients randomized to received cisapride 
(n=16) or placebo (n=16)  
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Neither total EN volume, daily protein nor caloric intake were statistically 
significantly different comparing patients receiving cisapride and patients receiving 
placebo. 
 
 
5.  Effect of cisapride administration on biological markers of metabolic activity   
 
• The nitrogen balance  
 
Nitrogen balance was measured in 22 patients (11 in each group) on day #3. 
The mean and median values were –7.27 ± 6.1 and –8 (min-max range:  –18, 
+1) respectively, in the cisapride group and were -9.91 ±14.7 and –8 (min-max 
range:  –51, +4) respectively, in the placebo group. The nitrogen balance was 
not statistically different between patients in the cisapride group and patients 
in the placebo group (P=0.59, two-sample t-test). 
.  
 
• Proportion of patients and  time to achieve the minimally required caloric 
intake based on anthropometric measures  
 
Minimal caloric intake was defined as 25 kcal/kg/day per patient. It was 
calculated when exact body weight was available (26 out of 32 patients). Mean 
body weight and mean BMI (body mass index) values were 74.9 ± 14.5 and 
26.5 ± 3.8, respectively in the cisapride group and values were 71.3 ± 16.9 and 
23.4 ± 4.3, respectively in the placebo group. Minimal caloric intake was 
reached only in a small percentage of patients: 35% after a mean time of 3.8 
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days respectively in the cisapride group and 25% after a mean time of 4 days 
respectively in the placebo group. The difference in the proportion of patients 
achieving the minimal caloric intake was not different between the two groups 
(P= 0.55, Log-rank test). 
 
 
6. Complications attributed to enteral nutrition 
 
No clinically relevant aspiration pneumonia cases were diagnosed during the study.  
 
Patients #2c (day #1-2-3 and #5), #12p (day #6), #22p (day #3) and #25p (day #5) 
experienced vomiting. All of them were nursed with oscillating beds without semi-
recumbent position and had high volume gastric residues. Only 2 of these patients 
were declared intolerant to EN (patients #2c and 22p). 
 
We did not observe diarrhea, and stools were rarely present during the study period. 
 
7. Agreement between quantification of residue by blind gastric suction and by 
suction performed under gastroscopic control 
 
Gastroscopy was planned between day #3 and day #5 according to the study protocol. 
It was performed only in 9 patients. The endoscopic examination confirmed the blind 
quantification of gastric aspirate in 6 cases (67% agreement). In the last 3 patients, 
gastric aspirate measured under gastroscopic control were 400mL (patient #5c), 
100mL (patient #15c) and 50mL (patient #18p) respectively. 
 
The clinical course of the three divergent results patient is detailed below: 
 
• Patient #5c: the gastric residue was not measured before the endoscopic 
examination. During the latter a gastric residue was measured and found 400 
ml. This residue is expected. Indeed, the EN was delivered at a rate of 65mL/h 
during 4 hours (260 ml) adding 300mL normal gastric secretion (2000ml/24h, 
around 300ml/4h). Then more than 500 mL could have been found if an ileus 
was present.  
 
• Patient #15c: the endoscopic examination revealed solid residue (around 
100ml), which could not be aspirated though the feeding tube. 
 
• Patient #18p: the endoscopic examination revealed a gastric aspirate of about a 
50mL.  
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DISCUSSION 
 
 
The present double blind randomized study indicates that the mean daily gastric 
residues over 6 days were lower in patients treated with cisapride compared with 
placebo. Overall mean oral, caloric and protein intake are similar in both groups, 
because the feeding protocol implicated to re-inject the gastric aspirate. If gastric 
residue had not been re-used, oral intake would have been lower in the placebo group. 
These findings are in accordance with the study conducted by Spapen et al [80], 
which demonstrated that patient treated with cisapride have a decrease gastric residue. 
 
Nitrogen balance was not statistically different between the two-randomization 
groups, even if the nitrogen balance was less negative in the cisapride group. Finally, 
no complication either related to enteral nutrition was observed except a few cases of 
vomiting, or related to cisapride administration in particular no arrhythmia was 
diagnosed. ECG monitoring was continuous and we were aware to avoid drug 
interaction with imidazole components and all other drugs concerned as mentioned in 
the methodology.  
 
Patient’s demographic characteristics were similar indicating that the two groups were 
comparable. In particular there are no significant differences in age, sex, SAPS II 
score, SOFA score, primary diagnosis, duration of ICU stay and outcome, even if a 
trend to a shorter ICU stay in the cisapride group is present. Time to initiation of 
enteral nutrition support, duration of enteral support and duration of oro-tracheal 
intubation are also similar. Furthermore, the interval time between ICU arrival and 
initiation of enteral feeding is 13 hours for both groups. In six patients out of nine, 
gastroscopy confirmed the gastric aspirate, which validates the result in 67% of cases.  
 
 
 
 
Review of the literature 
 
Relevant prospective studies about cisapride or other prokinetic drug administration 
and their effects on gastro-intestinal transit (GIT) and feeding tolerance (FT) on 
critically ill patients are listed below: 
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Investigator 
(reference) 
Prokinet
ic drug  
Design Duration 
of the 
study 
GIT 
studied 
FT 
studied 
Endpoints 
Spapen [80] C RC, no 
placebo 
7 days Yes Yes Acetaminophen absorption, 
Labeled test meal absorption, 
Volume of gastric aspirate 
Williams [169] C RPC 5 days No Yes Ability to absorb 80% of a 
gastric feed on the 5th day 
Goldhill [26] C DBRPC 2 days Yes No Acetaminophen absorption, 
Volume of gastric aspirate, 
Presence of bowel sounds 
Heyland [81] C DBRPC 2 days Yes No Acetaminophen absorption, 
Volume of gastric aspirate 
Mc Laren [50] M, C, E RPC; 
crossover 
2 days Yes No Acetaminophen absorption, 
Volume of gastric aspirate 
Mc Laren [170] M, C DBRPC 2 days Yes Yes Acetaminophen absorption, 
Volume of gastric aspirate 
Present study C DBRPC 6 days No Yes Volume of gastric aspirate 
 
C: cisapride, M: metoclopramide, E: erythromycin 
DBRPC: double blind randomized placebo controlled; RPC: randomized placebo 
controlled;  
 
Two studies observe the effect of cisapride on gastrointestinal transit and feeding 
tolerance in ICU patients. The first one, by Spapen et al [80], was an open prospective 
randomized control trial studying the benefit of adding cisapride to enteral nutrition 
on gastric tolerance in 21 patients. Patients were not feed before their inclusion in the 
study. The results showed that patients treated with cisapride (compared to no 
cisapride) had an accelerated gastric emptying time (measured by bedside 
scintigraphy) and a significantly lower mean gastric residue after 5 to 7 days of 
treatment. The second study, by Williams et al [169] recruited 27 ICU intolerant to 
EN patients, and administered 10 mg of cisapride or placebo in the nasogastric tube 
for 5 days in a randomized manner. Treatment was declared effective when patients 
were able to absorb 80% or more of a nasogastric feed by day 5. There was no 
significant difference in tolerance to enteral feeding between the two groups by day 5, 
but the amount of EN and the daily amount of cisapride prescribed or received were 
not described in the paper. Methodological description is unfocused, which precludes 
reproducibility.  
 
Two other studies observed the effect of cisapride on gastrointestinal transit only. 
Goldhill et al [26] investigate during 2 days the rate of absorption of rectally 
administered cisapride (60mg-30mg-30mg) versus placebo, on 27 randomized 
patients unfed before their recruitment. Enteral feeding was not permitted until the 
end of the study. Their study showed that rectal absorption of cisapride is similar 
between ICU patients and healthy subjects and that gastric emptying does not 
correlate with the volume of gastric aspirate or the presence of bowel sounds. Heyland 
et al [81] demonstrated that cisapride improves gastric emptying as measured by 
acetaminophen absorption model in a randomized, double blind, placebo-controlled 
study. Seventy-two patients were studied. No feeding was allowed during the study 
protocol, to allow measuring the difference in the absorption of acetaminophen 
between the two groups (cisapride or placebo). The acetaminophen test absorption 
was performed before and after the administration of 20 mg of cisapride suspension or 
an identical placebo. As acetaminophen absorption was enhanced after cisapride 
administration, they concluded that cisapride enhances gastric emptying. 
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Mc Laren et al [50, 170], performed studies comparing cisapride with other prokinetic 
drugs in critically ill, mechanically ventilated patients. In a first study [50], they 
compared sequential doses of prokinetic drugs (cisapride, erythromycin and 
metoclopramide), versus placebo, administered to 10 patients intolerant to EN (any 
measure of gastric residue > 150 ml) during a 48h study period. Gastric residual 
volume and plasma acetaminophen absorption were measured. All the three-
prokinetic drugs were effective in promoting gastric emptying. A second study was 
performed on 14 patients receiving either enteral cisapride 10 mg or metoclopramide 
10 mg every 6 hours with a total of 7 doses. EN was continued throughout the study if 
possible. Both cisapride and metoclopramide were effective to enhance gastric 
motility and improve tolerance to EN, but the study period was, as for the first study, 
of only 48 hours.  
 
The study of Spapen et al. is the only ones demonstrating long-term (>48h) 
improvement of gastro intestinal intolerance.  
 
 
Comparison with the literature 
 
The current double blind-randomized study was performed during a 6 days period and 
focussed on tolerance, as gastroparesis is often the limiting factor to achieve sufficient 
EN in critically ill mechanically ventilated patients. To note the absence of bowel 
sounds did not prevent delivering EN because it has no correlation with 
gastrointestinal and colonic transit [26, 61]. We defined high gastric aspirate by an 
gastric aspirate >250mL. Most studies use either 100 to 150mL [50, 170] up to 
200mL [97, 134, 169] or 250mL [171] as the designated level to indicate intolerance. 
But a well-performed study conducted by Mc Clave et al [152] has demonstrated that 
residual volume in normal healthy volunteers receiving total EN may exceed 150mL 
in as many as 15% of subjects. In critically ill patients receiving naso-gastric feedings, 
a wide range of residual volume (even up to 400mL) may be measured with no 
obvious intolerance. High gastric aspirate usually appears after 24 hours of feeding 
[27, 152, 172] and resolves after the introduction of a prokinetic agent. 
 
Time to initiation of EN, which corresponds to the time between admission and study 
inclusion, was short in the present study with a mean of 13 hours (± 14.6 hours-c 
group; ± 6.4-p group) in comparison to the other studies (varying between 24 and 72 
hours) [33, 81, 97, 101, 134, 135, 171, 173] Other studies did not mention the interval 
without EN [26, 50, 80, 170, 174]. Moreover, the majority of the studies also include 
patients in whom tolerance to EN is difficult to achieve [50, 81, 170].  
 
We observed a rate of intolerance of 18% (6/32 patients), which is comparable to 
other studies on critically ill patients. Montejo et al [134] in their multicenter study, 
had an intolerance rate of 15.2% (EN withdrawal as a consequence of incontrollable 
gastrointestinal complications), and Heyland et al [97] had an intolerance rate of 24%. 
No prokinetic drugs were administered in both studies. In the current study, the 6 EN 
intolerant patients received a parenteral nutrition, which was begun on day #3 (4 
patients) to #5 and EN was discontinued. A delay to achieve tolerance for the 
remaining 26 patients, as observed by Heyland et al in two different prospective 
cohort studies, was not observed in our patients. Indeed, in Heyland et al. first study 
on 99 patients [135], 74% patients were started on enteral feeding after an average 3.1 
days after ICU admission. Forty three percent of them achieved tolerance (received 
90% of daily estimated energy requirement for > 48h without gastro-intestinal 
dysfunction) after an average time of 5.8 days (range 1 to 14) from admission. In the 
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second study [163], on 73 patients suspect of intolerance to EN, 24 % patients failed 
early EN, and 42% achieved tolerance at 3.8 ±1.6 days (same definition as in the first 
study).  
 
A negative nitrogen balance was measured on day # 3. Retrospectively, it would have 
been more useful to collect this information at 2 different times. Indeed at day #3 
steady state EN was not achieved in many patients. Thus, it is not surprising that a 
negative nitrogen balance is found. In Moore et al [102] meta-analysis the nitrogen 
balance and nitrogen intake was measured at baseline (day #0 or #1), mid-study (day 
#4, #5 or #6) and end of study (day #7, #8 or #9). Although the difference in nitrogen 
balance between the two groups narrowed over time, it was always negative in the 
enteraly feed group: -11 at baseline, -3 at mid-study and -6 at the end of the study. 
Despite these negative results, total enteral feeding was proved more efficient than 
parenteral nutrition on septic post-operative complications. We found similar results (-
7.3-c group, respectively –9.9-p group) on day #3, assuming that minimal caloric 
were not reached for the majority of patients. The principal reasons usually given to 
explain the relative low protein intake have been well described and explain the 
present results. Indeed, medical staff does not insist to increase caloric intake and in 
some cases patients did not benefit from normal EN intake because they were 
extubated recently. In case of enteral feeding, gastric tolerance seems always to be the 
major problem as high gastric residue, vomiting and pulmonary aspiration are not well 
tolerated by nurses and medical staff. Enteral nutrition is also stopped for other 
reasons such as exams, transportation, surgery, nursing work over load etc. [172, 
173]. If we compare to recent studies, it is only when strict protocols are implemented 
that the percent of calories ordered/required can be raised from 78% to 100%, and 
ultimately the percent of calories delivered/required can be raised from 66% to 87% 
[172]. 
 
Finally, only critically ill mechanically ventilated patients were included in the study. 
Most of them received analgesia (morphine or sufentanyl in low quantity) and 
sedation (propofol, midazolam), and some time needed vasoactive support. In 
comparison to placebo administration, the administration of cisapride was able to 
normalize gastric residue particularly when morphine or insulin administration were 
co administrated. 
 
Future investigations should evaluate the long-term benefit of early enteral nutrition 
associated with prokinetic administration in terms of ICU length stay, outcome and 
cost effectiveness. New prokinetic drug similar to cisapride or erythromycin but 
without the secondary effects (drug interactions for cisapride, anti- microbial activity 
and low therapeutic window) should be investigate. Cefazolin was recently tested 
[175] but without success in critically ill patients. 
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CONCLUSIONS 
 
This double-blind randomized study allows drawing the following conclusions: 
 
In critically ill, mechanically ventilated patients, gastric emptying is reduced by fifty 
percent if cisapride is added to a standard enteral feeding protocol. Tolerance to 
enteral nutrition is enhanced by the administration of cisapride if one considers the 
gastric aspirate as the reflection of tolerance. The strict observance of an enteral 
feeding protocol is the clue to promote efficiently oral intake and can compensate in 
terms of caloric intake for the delayed gastric emptying. Moreover, time to initiation 
of enteral nutrition can be very short if a strict protocol is applied.
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APPENDIX I 
 
 
 
Figure #1 
 
 
 
 
 
Anatomy of the stomach 
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Figure #2 
 
 
 
 
Motor activity of proximal stomach responsible for gastric emptying 
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Figure #3 
 
 
 
 
Electrical and motor activity of distal stomach responsible for gastric emptying of 
digestible solids 
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Figure #4 
 
 
 
 
Motor activity responsible for gastric emptying of indigestible solids 
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Figure #5 
 
 
 
 
Illustration of small intestine cells 
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Figure #6 
 
 
 
 
Physiology of gastric and small intestine emptying. 
 
 
 
 
 
 
 
 
Various factors that influence gastric emptying are depicted. Location of mechanical and osmotic 
receptors (1 and 3) as determined by human studies. Other receptors localized by studies in dogs. 
Abbreviations: CCK-cholecystokinine; GIP-gastric inhibitory polypeptide; VIP-vasoactive intestinal 
polypeptide 
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Figure #7 
 
 
 
 
Illustration of stimulation and homing of IgA producing plasma cells 
 
IgA is secreted once cells mature in the lamina propria 
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Figure #8 
 
 
 
 
Diagram of development of multiple organ failure 
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Figure #9 
 
 
 
 
Diagram illustrating the progressive atrophy of the villous height and crypt depth, 
bacterial proliferation and then translocation through the atrophied epithelial barrier 
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Figure #10 
 
 
 
 
Postoperative septic complications  
 
 
 
Postoperative septic complications (phase II)
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Total septic complication
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* p<0.05
 
adapted from Moore et
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 72 bis
Rate of administration of enteral feeding: 250 ml/11h 
Administration of cisapride or his placebo every 6 hours A B  
 
 
 Larger gastric aspirate 
(>250mL):  
 
Normal gastric aspirate 
(≤ to 250mL): 
After 11 hours, 1 hour fast and 
then do the gastric aspirate  
 
 • Stop enteral feeding 
• Give back the total gastric aspirate 
• Give 10 ml of cisapride or his placebo (c/p) 
• Wait 4 hours  
• Then do another gastric residue 
 
 
 
 
 
• Give back the total gastric aspirate 
• Give 10 ml of cisapride or his placebo (c/p) 
• Increase the rate of administration from 500mL 
(250mL/11 h) on day 1 (24hours), to 1000mL 
(500mL/11h) on day 2 
Larger gastric
aspirate (>250mL):
Start B 
Normal gastric aspirate 
(≤ to250 ml) 
Start A 
 
Larger gastric aspirate 
(>250mL): 
 
 
 
Normal gastric aspirate 
(≤ to 250mL): 
 
 • Give back the total gastric aspirate 
• Wait 2 hours 
• Give 10 ml of c/p 
• Wait 4 hours 
• Then do another gastric residue 
 
 
 
 
 
• Give back the total gastric aspirate 
• Give 10 ml of cisapride or his placebo (c/p) 
• Increase the rate of administration from 1000mL 
(500mL/11 h) on day 2 (24hours), to 1500mL 
(750mL/11h) on day 3 
Larger gastric
aspirate (>250mL):
Start B 
Normal gastric aspirate 
(≤ to250 ml) 
Start A 
 
 Larger gastric aspirate 
(>250mL):   
 
Normal gastric aspirate 
(≤ to 250mL): 
 Normal gastric aspirate 
(≤ to250 ml) 
Start A 
 • Give back only 250ml of the gastric aspirate 
• Wait 4 hours  
• Then do another gastric residue  
 
 
 
 
• Give back the total gastric aspirate 
• Give 10 ml of cisapride or his placebo (c/p) 
• Increase the rate of administration from 1500ml 
(750ml/11h) to give 25 to 30 kcal/kg/day per 
patient Call the doctor in charge of the patient 
Stop enteral nutrition. Introduce a total parenteral nutrition. 
  
Still measure gastric aspirate at the same time points  
Larger gastric aspirate 
(>250mL): 
  
Figure #12 
 
 
 
Gastroscopy procedure: 
 
 
 
 
 
Exact time of the exam known: 
 
• Stop the enteral nutrition one hour before the exam 
• Just before the exam to a gastric aspirate 
• Note the exact amount of the gastric aspirate in mL 
• Do not give that gastric aspirate back to the patient and throw it away 
• Remove the naso-gastric tube 
• Proceed as soon as possible to the gastroscopy, which should confirm the 
emptiness of the stomach 
• Insert a new naso-gastric tube after the exam and assess its correct position (air 
inflation through a 60mL syringe and auscultation of a gastric sound). In case 
of doubt about its correct position, do a chest x-ray. 
• Start the enteral nutrition at the rate reached before the exam with a new 24-
hours time scale. 
 
 
 
 
 
Exact time of the exam unknown: 
 
• Stop the enteral nutrition just before the exam and proceed to a gastric aspirate 
• Note the exact amount of the gastric aspirate in mL 
• Do not give that gastric aspirate back to the patient and throw it away 
• Remove the naso-gastric tube 
• Proceed to the gastroscopy, which should confirm the emptiness of the 
stomach 
• Insert a new naso-gastric tube after the exam and assess its correct position (air 
inflation through a 60mL syringe and auscultation of a gastric sound). In case 
of doubt about its correct position, do a chest x-ray. 
• Start the enteral nutrition at the rate reached before the exam with the same 
24-hours time scale. 
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Table #2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 Bad outcome 
# 4d-12-19-21d-22d 
# 30 (died after transfer in 
France) 
# 14 (died on day 3) 
7 Bad outcome 
# 3d-8-10-15-17-27 
# 7 died on day 3 
9 Good outcome
# 1d-13-16-18-20-
23-24-25-32d 
9 Good outcome 
# 2-5d-6d-9-11-26-
28-29-31 
TRIAL PROFIL 
3 intolerant 
# 21d-22d-24 
13 tolerant  
# 1d-4d-12-13-14-16-18-19-
20-23-25-30-32d 
3 intolerant  
# 2-3d-27 
13 tolerant  
# 5d-6d-7-8-9-10-11-
15-17-26-28-29-31 
16 assessable  patients 
2 days EN: # 21 d 
3 days EN: # 14-24 
4 days EN : # 20-23-32d 
5 or more days EN: # 1d-4d-12-13-16-18-19-25-30 
PN and EN : # 22 d 
16 assessable  patients 
2 days EN : # 7-27-31 
 
4 days EN : # 2-3d 
5 or more days EN: # 5d-6d-8-9-10-11-15-17-
26-28-31
Placebo groupe: 
16 randomised patients 
# 1d-4d-12-13-14-16-18-19-20-
21d-22d-23-24-25-30-32 d 
Cisapride groupe :  
16 randomised patients 
# 2-3d-5d-6d-7-8-9-10-11-
15-17-26-27-28-29-31 
32 Patients enrolled:  
# 1 to 28 in Neuchâtel 
# 29 to 32 in Geneva 
d: diabetics patients 
#: number 
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Graphic #2 
 
 
 
 
  
Mean daily gastric aspirate
25
75
125
175
1 2 3 4 5 6
Days
m
l
Cisaprid groupe placebo group
 
 
 
Mean daily gastric aspirate 
 
 
Day 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 Mean 
(SD) 
Median 
Cisapride 
group 
(mL) 
71 87 83 99 97 59 81 54 33 33 58 94 71  
(+/- 23) 
76 
Placebo 
group 
(mL) 
74 70 160 136 135 129 101 151 143 181 179 121 132 
(+/- 36) 
136 
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APPENDIX II 
 
Results of the statistical analysis  
 
We used a generalized linear mixed model with random effect to analyze gastric 
aspirate: 
 
Generalized linear models                          No. of obs      =       301 
Optimization     : ML: Newton-Raphson              Residual df     =       269 
                                                   Scale param     =  10235.88 
Deviance         =  2753451.129                    (1/df) Deviance =  10235.88 
Pearson          =  2753451.129                    (1/df) Pearson  =  10235.88 
 
Variance function: V(u) = 1                        [Gaussian] 
Link function    : g(u) = u                        [Identity] 
Standard errors  : Modified Sandwich 
 
Log likelihood   = -1799.849432                    AIC             =  12.17176 
BIC              =  2753268.502 
 
                            (standard errors adjusted for clustering on patno) 
------------------------------------------------------------------------------ 
             |               Robust 
         res |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         trt |  -33.63636   5.00e-12        .   0.000    -33.63636   -33.63636 
   _Ipatno_2 |   214.5455   2.34e-12        .   0.000     214.5455    214.5455 
   _Ipatno_3 |    132.197   4.53e-12        .   0.000      132.197     132.197 
   _Ipatno_4 |   83.44697   4.46e-12        .   0.000     83.44697    83.44697 
   _Ipatno_5 |  -5.416667   2.34e-12        .   0.000    -5.416667   -5.416667 
   _Ipatno_6 |        -20   2.34e-12        .   0.000          -20         -20 
   _Ipatno_7 |  -11.66667   2.38e-12        .   0.000    -11.66667   -11.66667 
   _Ipatno_8 |         10   2.34e-12        .   0.000           10          10 
   _Ipatno_9 |   55.90909   2.34e-12        .   0.000     55.90909    55.90909 
  _Ipatno_10 |        -24   2.34e-12        .   0.000          -24         -24 
  _Ipatno_11 |     -26.25   2.34e-12        .   0.000       -26.25      -26.25 
  _Ipatno_12 |   135.5303   4.52e-12        .   0.000     135.5303    135.5303 
  _Ipatno_13 |   75.80808   4.47e-12        .   0.000     75.80808    75.80808 
  _Ipatno_14 |   88.36364   4.53e-12        .   0.000     88.36364    88.36364 
  _Ipatno_15 |   92.85714   2.34e-12        .   0.000     92.85714    92.85714 
  _Ipatno_16 |   156.9886   4.45e-12        .   0.000     156.9886    156.9886 
  _Ipatno_17 |     21.625   2.34e-12        .   0.000       21.625      21.625 
  _Ipatno_18 |  -46.81818   4.43e-12        .   0.000    -46.81818   -46.81818 
  _Ipatno_19 |  -32.13636   4.43e-12        .   0.000    -32.13636   -32.13636 
  _Ipatno_20 |   82.79221   4.43e-12        .   0.000     82.79221    82.79221 
  _Ipatno_21 |   243.3636   4.53e-12        .   0.000     243.3636    243.3636 
  _Ipatno_22 |    89.2803   4.46e-12        .   0.000      89.2803     89.2803 
  _Ipatno_23 |   24.48864   4.42e-12        .   0.000     24.48864    24.48864 
  _Ipatno_24 |   197.7922   4.43e-12        .   0.000     197.7922    197.7922 
  _Ipatno_25 |   34.54545   4.43e-12        .   0.000     34.54545    34.54545 
  _Ipatno_26 |       -9.5   2.34e-12        .   0.000         -9.5        -9.5 
  _Ipatno_28 |         60   2.34e-12        .   0.000           60          60 
  _Ipatno_29 |   48.33333   2.37e-12        .   0.000     48.33333    48.33333 
  _Ipatno_32 |   79.36364   4.43e-12        .   0.000     79.36364    79.36364 
  _Ipatno_33 |      6.625   2.34e-12        .   0.000        6.625       6.625 
  _Ipatno_34 |  -58.63636   4.43e-12        .   0.000    -58.63636   -58.63636 
       _cons |   63.63636   4.42e-12        .   0.000     63.63636    63.63636 
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We used a random-effect GLS regression to analyse the daily caloric intake: 
 
Random-effects GLS regression                   Number of obs      =       172 
Group variable (i) : patno                      Number of groups   =        32 
 
R-sq:  within  = 0.0000                         Obs per group: min =         2 
       between = 0.0001                                        avg =       5.4 
       overall = 0.0001                                        max =         6 
 
Random effects u_i ~ Gaussian                   Wald chi2(1)       =      0.01 
corr(u_i, X)       = 0 (assumed)                Prob > chi2        =    0.9396 
 
------------------------------------------------------------------------------ 
    calories |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         trt |    11.7924     155.74     0.08   0.940    -293.4524    317.0372 
       _cons |    781.796   109.9024     7.11   0.000     566.3912    997.2007 
-------------+---------------------------------------------------------------- 
     sigma_u |  378.42789 
     sigma_e |  510.70325 
         rho |  .35445207   (fraction of variance due to u_i) 
The daily oral intake in ml: 
 
Random-effects GLS regression                   Number of obs      =       172 
Group variable (i) : patno                      Number of groups   =        32 
 
R-sq:  within  = 0.0000                         Obs per group: min =         2 
       between = 0.0002                                        avg =       5.4 
       overall = 0.0000                                        max =         6 
 
Random effects u_i ~ Gaussian                   Wald chi2(1)       =      0.00 
corr(u_i, X)       = 0 (assumed)                Prob > chi2        =    0.9818 
 
------------------------------------------------------------------------------ 
  oralintake |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         trt |  -3.042752   133.1757    -0.02   0.982    -264.0622    257.9767 
       _cons |   726.2154   93.97729     7.73   0.000     542.0233    910.4075 
-------------+---------------------------------------------------------------- 
     sigma_u |   321.9862 
     sigma_e |  443.40905 
         rho |  .34525376   (fraction of variance due to u_i) 
 
And the daily protein intake:  
 
Random-effects GLS regression                   Number of obs      =       172 
Group variable (i) : patno                      Number of groups   =        32 
 
R-sq:  within  =      .                         Obs per group: min =         2 
       between = 0.0010                                        avg =       5.4 
       overall = 0.0007                                        max =         6 
 
Random effects u_i ~ Gaussian                   Wald chi2(1)       =      0.04 
corr(u_i, X)       = 0 (assumed)                Prob > chi2        =    0.8342 
 
------------------------------------------------------------------------------ 
    proteins |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         trt |   1.463353   6.992691     0.21   0.834    -12.24207    15.16878 
       _cons |   32.02748   4.934825     6.49   0.000      22.3554    41.69956 
-------------+---------------------------------------------------------------- 
     sigma_u |  17.171088 
     sigma_e |  22.220395 
         rho |  .37388939   (fraction of variance due to u_i) 
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